

1 **Plasma microRNA profiling for malaria disease: association with severity and *P. falciparum***
2 **biomass**

3 Running Title: microRNA of severity and *P. falciparum* biomass

4
5 Himanshu Gupta[#], Mercedes Rubio[#], Antonio Siteo, Rosauro Varo, Pau Cisteró, Lola Madrid,
6 Inocencia Cuamba, Alfons Jimenez, Xavier Martíáñez-Vendrell, Diana Barrios, Lorena Pantano,
7 Allison Brimacombe, Mariona Bustamante, Quique Bassat^a, Alfredo Mayor^a

8
9 Author affiliations: ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain (H.
10 Gupta, M. Rubio, R. Varo, P. Cisteró, A. Jimenez, X. Martíáñez-Vendrell, D. Barrios, A.
11 Brimacombe, M. Bustamante, Q. Bassat, A. Mayor); Centro de Investigação em Saúde de Manhiça
12 (CISM), Manhiça, Mozambique (A. Siteo, R. Varo, L. Madrid, I. Cuamba, Q. Bassat, A. Mayor);
13 Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
14 (A. Jimenez, M. Bustamante, Q. Bassat, A. Mayor); Department of Biostatistics, Harvard T.H.
15 Chan School of Public Health, Boston, MA, USA (L. Pantano); Universitat Pompeu Fabra (UPF),
16 Barcelona, Spain (M. Bustamante); ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain (Q.
17 Bassat); Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu
18 (University of Barcelona), Barcelona, Spain (Q. Bassat)

19
20 [#]equal contribution

21 ^aThese authors share senior authorship

22
23 **Abstract word count: 148**

24 **Text word count: 3485**

25 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

19th Dec

Gupta et al

26 Address for correspondence: Dr. Himanshu Gupta, ISGlobal, Hospital Clínic, Universitat de
27 Barcelona, Carrer Rosselló 153 (CEK Bldg), E-08036 Barcelona, Spain; E-mail:
28 himanshu.gupta@isglobal.org; himanshugupta.hcu@gmail.com

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Abstract**

52

53 Severe malaria (SM) is a major public health problem in malaria-endemic countries. Sequestration
54 of *Plasmodium falciparum* (*Pf*) infected erythrocytes in vital organs and the associated
55 inflammation leads to organ dysfunction. MicroRNAs (miRNAs), which are rapidly released from
56 damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of SM. This
57 study applied next-generation sequencing to evaluate the differential expression of miRNAs in SM
58 compared to uncomplicated malaria (UM). Six miRNAs were associated with *in vitro Pf*
59 cytoadhesion, severity in Mozambican children and *Pf* biomass. Relative expression of hsa-miR-
60 4497 quantified by TaqMan-RT-qPCR, was higher in SM children plasmas compared to that of UM
61 ($p < 0.048$), and again correlated with *Pf* biomass ($p = 0.033$). These findings suggest that different
62 physiopathological processes in SM and UM lead to differential expression of miRNAs and pave
63 the way to future studies aiming to assess the prognostic value of these miRNAs in malaria.

64

65

66 **Keywords:** miRNA, severe malaria, biomarkers, Next-generation sequencing, Histidine-rich
67 protein 2

68

69

70

71

72

73

74

75

76 **Introduction**

77

78 Case fatality rates for *Plasmodium falciparum* (*Pf*) severe malaria (SM) remain unacceptably high
79 in young African children (1). Early detection and prompt treatment of SM are critical to improve
80 the prognosis of sick children. Unfortunately, clinical signs and symptoms in many malaria
81 patients, particularly at the beginning of the infection, may not adequately indicate the potential for
82 the infection to trigger severe or life-threatening disease. Moreover, in malaria-endemic areas,
83 where immunity to malaria is progressively acquired, the detection of peripheral *Pf* parasitemia in
84 sick children does not necessarily prove that malaria is the cause of the severe pathology observed,
85 given that many individuals may carry parasites without expressing clinical malarial disease (2).

86

87 Sequestration of *Pf* infected erythrocytes (iEs) (3) in vital organs is believed to constitute a key
88 pathogenic event leading to SM, as has been shown in post-mortem parasite counts in patients who
89 died with cerebral malaria (CM) (4, 5). This extensive sequestration of parasitized erythrocytes in
90 the microvasculature, together with the production of inflammatory mediators, leads to the
91 dysfunction of one or more peripheral organs, such as the lungs (acute respiratory distress
92 syndrome), kidneys (acute kidney injury) or brain (coma) (6, 7). This tissue-specific tropism of *Pf*
93 parasites is mediated by the *Pf* erythrocyte membrane protein-1 (PfEMP1) which can bind to
94 different host receptors on the capillary endothelium, uninfected erythrocytes and platelets (8, 9)
95 such as endothelial receptor of protein C (ePCR), gC1qR, Intercellular adhesion molecule-1, CD36,
96 chondroitin sulfate A or complement receptor 1 (10).

97

98 Efforts have been made to identify biomarkers of SM which could be used for prevention of the
99 severity of disease, and for early diagnosis (11). Several biomarkers related to endothelial activation
100 and immune dysfunction have been associated with different malaria-derived severe pathologies

101 (11-14). Plasma levels of histidine-rich protein 2 (HRP2), a parasite-specific protein secreted by the
102 parasite during its blood cycle, has been used as a biomarker of total parasite biomass (circulating
103 and sequestered parasites) (15, 16) and therefore as a prognostic marker of the total parasite
104 biomass and as a better proxy marker for SM than peripheral parasitemia (16). Organ damage and
105 pathological disease states have also been associated with the rapid release of microRNAs
106 (miRNAs) into the circulation, a class of endogenous small non-coding RNAs (18-24 nucleotides)
107 (17). As secreted miRNAs can be detected in biological fluids such as plasma (18), they are
108 currently being explored as promising non-invasive biomarkers to monitor organ functionality and
109 tissue pathophysiological status. The content of miRNAs in the host is influenced by host-pathogen
110 interactions (19). Sequestration of erythrocytes infected with *P. berghei* in mice brains has been
111 demonstrated to modify the miRNA expression in cells (20). Similarly, sequestration of *P. vivax*
112 gametocytes in the bone marrow has been associated with transcriptional changes of miRNAs
113 involved in erythropoiesis (21). The aforementioned evidence suggests that *Plasmodium* parasites,
114 although not able to produce miRNAs (22), could affect the production of organ-specific host
115 miRNAs, pointing towards the potential of these small molecules to detect SM associated organ
116 injury (23) and to confirm the contribution of malaria in the chain of events leading to death
117 through the analysis of postmortem tissues (23).

118
119 This study was conducted under the hypothesis that miRNA levels in plasma are differentially
120 expressed among children with severe and uncomplicated malaria due to the parasite sequestration
121 in vital organs of severely ill children. To identify promising biomarkers for SM, a small RNA
122 next-generation sequencing (NGS) was applied to select miRNAs that were differentially expressed
123 by human brain endothelial (HBE) cells exposed to *Pf*iEs selected for cytoadhesion to endothelial
124 receptor of protein C, the main host receptor associated with SM (9), compared to those exposed to
125 non-cytoadherent iEs, and non-infected erythrocytes (niEs), as well as by Mozambican children

126 with SM compared to children with uncomplicated malaria (UM) (Figure 1). miRNAs that were
127 differentially expressed in both analyses, together with the *Pf* biomass-associated miRNAs
128 (correlation coefficient >0.50 (24)), were quantitatively confirmed in an independent validation
129 cohort set of Mozambican children with SM and UM using TaqMan reverse transcriptase
130 quantitative PCRs (RT-qPCRs).

131

132 **Material and Methods**

133

134 **Study population**

135

136 Plasma samples used to assess miRNA levels were collected in two case-control studies conducted
137 in Manhiça District (southern Mozambique) during 2006 (N=113) and 2014 (N=91). Briefly, the
138 cases were children under five years of age admitted to the Manhiça District Hospital with SM and
139 controls were outpatient children with UM. Details on SM and UM criteria, case management,
140 sample collection and storage, and laboratory blood analysis are included in the Technical
141 Appendix.

142

143 The study protocols for each of the two case-control studies from which this analysis was derived
144 were approved by the National Mozambican Ethical Review Committee (Mozambique) and
145 Hospital Clínic (Barcelona, Spain). A signed written informed consent was obtained from all
146 participants' guardian or parent during the original studies.

147

148 **Parasitological determinations**

149

150 Thick and thin blood films were prepared to quantify *Pf* parasitaemia. Approximately half of a
151 60µL dried blood drop on Whatman-903 filter paper was used to extract parasite DNA followed by
152 a real-time quantitative PCR (qPCR) targeting the *Pf* 18S rRNA gene (25, 26). HRP2 levels were
153 quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits and an
154 in-house highly sensitive quantitative bead suspension array (qSA) based on Luminex technology
155 (Technical Appendix).

156

157 ***Pf* cytoadhesion assays**

158

159 Cytoadhesion assays were performed to discover the differential expression of miRNAs. HBE cells
160 were incubated with *Pf*-iEs at the trophozoite stage of the ePCR-binding FCR3 strain (ePCR-iE;
161 which expresses the PfEPM1 protein that binds to ePCR receptor) and the 3D7 strain (3D7-iE; a
162 strain without the protein that binds to ePCR receptor). Non-infected erythrocytes were used as
163 negative control. Details on cytoadhesion assays are included in the Technical Appendix. The cell-
164 conditioned media of each group were collected after 1hr (t1) and 24hrs of stimulation (t24) and
165 subjected to RNA extraction followed by small-RNA sequencing.

166

167 **Molecular procedures, gene target prediction and data analysis**

168

169 RNA was extracted from cell-conditioned media (3ml) and plasma samples (1ml) using the
170 miRNeasy tissues/cells kit and miRNeasy Plasma/Serum kit, respectively, with the use of 5µg
171 UltraPure™ glycogen/sample. Given that the plasma samples were conserved in heparin, RNA was
172 precipitated with LiCl as described elsewhere (27). Purified RNA was subjected to library
173 preparation, pooling and sequencing using a HiSeq 2000 (Illumina) platform following the protocol
174 for small RNAs (28), for more details see the Technical Appendix. A previously published pipeline

175 (28) was used to assess the sequencing quality, identification and quantification of small RNAs,
176 normalization and other species RNA contamination (Technical Appendix). To detect miRNAs and
177 isomiRs, reads were mapped to the precursors and annotated to miRNAs or isomiRs using miRBase
178 version 21 with the miraligner (29). DESeq2 R package v.1.10.1 (R3.3.2) (30) was used to perform
179 an internal normalization.

180

181 Fifty μ l of plasma from the Mozambican children (2014) with no haemolysis were used for RNA
182 extraction as described above followed by RT-qPCR. Details on RT-qPCR and endogenous controls
183 (ECs) are included in the Technical Appendix. miRNA relative expression levels (RELs) were
184 calculated with the $2^{-\Delta Ct}$ method, where $\Delta Ct = [Ct(\text{miRNA}) - \text{Mean Ct}(\text{ECs})]$, considering
185 efficiencies of 100% for all the miRNAs and ECs (31).

186

187 The selected miRNAs were screened through different gene target prediction programs such as
188 DIANA-microT-CDS, MiRDIP, MirGate, and TargetScan (Technical Appendix).

189

190 Differential expression of miRNAs and isomiRs was assessed using DESeq2 and IsomiRs packages
191 in R (29, 32), for more details see the Technical Appendix. All statistical analyses were performed
192 using R3.3.2 and graphs were prepared with GraphPad (Technical Appendix).

193

194

195

196

197

198

199

200 **Results**

201

202 **Discovery phase**

203

204 **miRNA expression by HBE cells**

205

206 The ePCR binding *Pf* strain (FCR3; ePCR-iE) showed higher levels of cytoadhesion to HBE cells
207 (mean of 32.60 iE per 500cells, standard deviation [SD]:4.87) than a non-binding *Pf* (3D7; 3D7-iE)
208 strain (3.20, SD:1.06; p=0.001) and non-infected erythrocytes (3.12, SD:0.39; p=0.001) (Appendix
209 Figure 1). Three replicates of the media collected from each cytoadhesion assay after one (t1) and
210 24 hours (t24) were sequenced, giving a total of more than 200 million reads per lane, with a mean
211 of 12.10 million reads (SD=13.31) per sample (Table 1; Figure 2A; Appendix Table 1). The mean
212 percentage of miRNAs in the media samples analysed was 4.01% (SD=2.93) and a mean of 203
213 (SD=93.82) distinct miRNAs (a minimum of 101 and a maximum of 465) were detected (Appendix
214 Table 1). The ten most expressed miRNAs for all samples at t1 and t24 time points are described in
215 Figure 2B. No contamination with RNA from other species was observed.

216

217 One hour after incubating the HBE cells with *Pf* infected and non-infected erythrocytes, 111
218 miRNAs were found to be differentially expressed in cell-condition media of niE and ePCR-iE, 76
219 of them being downregulated and 35 upregulated in ePCR-iE compared to niE (Figure 2C;
220 Appendix Table 2). At this same time point, 100 miRNAs were differentially expressed in cell-
221 condition media of 3D7-iE and ePCR-iE, 67 were downregulated and 33 upregulated in ePCR-iE
222 compared to 3D7-iE (Figure 2D; Appendix Table 3). Overall, 89 miRNAs were differentially
223 expressed in ePCR-iE compared to both niE and 3D7-iE, 28 and 61 of which were upregulated and
224 downregulated, respectively, in ePCR-iE. There were no differentially expressed miRNAs between

225 niE and 3D7-iE cell-condition media. At t24, only hsa-miR-451a was significantly upregulated in
226 cell-condition media of ePCR-iE with respect to niE and 3D7-iE. There were no significantly
227 different miRNAs found between niE and 3D7-iE cell-condition media. All differentially expressed
228 isomiRs were from the selected miRNAs and none of them presented any modifications in the seed
229 region.

230

231 **miRNAs expression in plasmas from Mozambican children with malaria of varying severity**

232

233 Out of 113 plasma samples collected from Mozambican children with SM (N=57) and UM (N=56)
234 in 2006, 11 samples were discarded because of haemolysis (N=5; OD₄₁₄>0.2) (33), and because no
235 peak was observed between 133-150 nucleotides (typical size for miRNAs plus library adaptors) on
236 the bioanalyzer results after library preparation (N=6). Among the 102 sequenced samples (SM=53;
237 UM=49), 19 samples (9 SM; 10 UM) were further excluded because of the low number of miRNA
238 reads (<10,000 reads). Finally, samples from 83 children (44 with SM and 39 with UM) were
239 included in the analysis (Table 2). The characteristics of Mozambican children are presented in
240 Table 2.

241

242 The sequencing of the 83 plasma samples yielded a mean of 9.42 million reads (SD=6.4) per
243 sample (Figure 2A; Table 1; and Appendix Table 4). The mean percentage of miRNAs per plasma
244 samples was 20.5% (SD=13.2), with a mean of 395 (SD=169) distinct miRNAs detected (a
245 minimum of 116 and a maximum of 786; Appendix Table 4). The total number of miRNAs
246 detected across samples was 1450. The ten most expressed miRNAs can be found in Figure 2B. No
247 contamination with RNA from other species was observed.

248

249 hsa-miR-122-5p was found upregulated in children with SM (Table 3). In the sub-analysis by signs
250 of severity, five miRNAs were found associated with SA, prostration and ARD (Table 3). Twelve
251 miRNAs were found associated with PM-agglutination and cytoadhesion to g1CqR (Table 3). No
252 associations were observed between miRNA counts and rosetting, CD36 and CD54. After adjusting
253 for multiple comparisons, three (hsa-miR-10b-5p, hsa-miR-378a-3p and hsa-miR-4497) out of the
254 1450 miRNAs (identified in RNA sequencing data) were found to correlate with HRP2 levels
255 determined by qSA (Spearman analysis; Figure 3). Similar correlations were observed when HRP2
256 levels were determined by ELISA (Appendix Table 5). miRNAs were neither associated with
257 hepatomegaly nor with splenomegaly. All differentially expressed isomiRs between children with
258 SM and UM belong to the differentially expressed miRNAs, with no modifications in the seed
259 region.

260

261 **Validation cohort**

262

263 Among the 89 miRNAs differentially expressed in cell-condition media of HBE cells exposed to
264 niE and 3D7-iE compared to ePCR-iE, 5 miRNAs were further confirmed to be differentially
265 expressed between children with SM and UM. These five miRNAs (hsa-miR-122-5p, hsa-miR-
266 320a, hsa-miR-1246, hsa-miR-1290 and hsa-miR-3158-3p) along with hsa-miR-4497 miRNA,
267 which had a correlation coefficient with HRP2 higher than 0.5 (Figure 3), were selected for
268 TaqMan-RT-qPCRs validation in an independent cohort of children with SM and UM recruited in
269 2014. Among the 91 plasma samples collected from these children, 21 were discarded because of
270 haemolysis ($OD_{414} > 0.2$) (33). Out of the 70 remaining samples, 40 and 30 samples were collected
271 from children with SM and UM, respectively (Table 2). The characteristics of Mozambican children
272 are presented in Table 2.

273

274 All samples tested by RT-qPCR amplified the exogenous control (ath-miR-159a) with a Ct
275 value<18 and a coefficient of variance (CV) <5%, suggesting the correct RNA extraction and
276 cDNA preparation. hsa-miR-191-5p (CV=4.8%, basemean=3953.3, log₂fold change (FC)=-0.02 and
277 SD=0.56), hsa-miR-30d-5p (CV=4.9%, basemean=14172.31, FC=0.01 and SD=0.61) and hsa-miR-
278 148a-3p (CV=5%, basemean=111593.08, FC=0.11 and SD=0.82) were selected as a panel of ECs
279 for RT-qPCR analysis. Among these three, the NormFinder stability value was 0.044 for the
280 combination of hsa-miR-30d-5p and hsa-miR-191-5p, and were thus selected as ECs. No
281 statistically significant differences were found when Ct values of exogenous and two endogenous
282 controls were compared between SM and UM samples (Appendix Figure 2). Standard curves for all
283 miRNAs (ECs and selected miRNAs) were performed, giving efficiencies between 91.1% - 103.8%
284 (Appendix Table 6), which were assumed as 100% to calculate the relative expression values using
285 the $2^{-\Delta Ct}$ method (31).

286

287 The relative expression levels of hsa-miR-3158-3p and hsa-miR-4497 were significantly higher in
288 children with SM than UM (p<0.05) as shown in Figure 4. hsa-miR-3158-3p levels were higher in
289 children with prostration, multiple seizures and ARD compared to UM (p<0.05; Figure 5). Severe
290 anaemia and ARD symptoms were associated with higher hsa-miR-4497 levels (p<0.05; Figure 5).
291 No such associations were observed for CM and hypoglycaemia. RELs of hsa-miR-3158-3p and
292 hsa-miR-4497 were found positively correlated with HRP2 levels quantified by qSA (p<0.05;
293 Figure 6), with similar correlations observed when HRP2 levels were determined by ELISA
294 (Appendix Table 5).

295

296 **miRNA gene target prediction**

297

298 A total of 87 putative targets for hsa-miR-3158-3p and hsa-miR-4497 miRNAs were identified,
299 none of which were shared by both miRNAs (Appendix Table 7). Forty-five experimentally
300 validated mRNA targets were predicted for hsa-miR-3158-3p and 42 for hsa-miR-4497. The
301 predicted targets were found to be involved in a broad range of biological processes (Appendix
302 Table 8). However, significance was lost when adjusted by the Benjamini-Hochberg method. None
303 of the target genes were clustered under the KEGG pathway with p value <0.05.

304

305 **Discussion**

306

307 As microRNAs can reflect disease states and organ damage due to their specificity to cell type (17),
308 they have the potential to provide a new screening method for early detection of pathological *Pf*
309 sequestration and may consequently become an effective prognosis tool for severe malaria.
310 Moreover, the detection of miRNAs associated with organ damage in host biofluids may provide an
311 alternative to post-mortem autopsies for determining the presence of parasites in host vital organs.
312 This approach creates new opportunities to develop malaria diagnostic tools that can guide
313 treatment decisions, and to understand the role of human miRNAs in several disease conditions
314 (23).

315

316 In the discovery phase, 89 miRNAs were found to be differentially expressed in the media of HBE
317 cells after incubation with an ePCR-cytoadherent *Pf* strain as compared with non-cytoadherent
318 parasites and non-infected erythrocytes. In addition, fifteen miRNAs in plasma samples obtained
319 from Mozambican children were associated with SM, with specific severity symptoms, and with the
320 cytoadherent *Pf* phenotype, compared to UM and non-cytoadherent parasites. In the validation
321 phase, the higher abundance of hsa-miR-3158-3p and hsa-miR-4497 in SM children compared to
322 children with UM was further confirmed. Prostration, multiple seizures, SA and ARD symptoms of

323 severity were associated with higher levels of hsa-miR-3158-3p and hsa-miR-4497. hsa-miR-4497
324 levels were also positively correlated with the parasite biomass as quantified by the levels of HRP2
325 both in the discovery and validation phases. Overall, these findings suggest that different
326 physiopathological processes in SM and UM lead to differential expression of miRNAs in plasma.
327
328 HBE cells released a high number of the miRNAs when they were stimulated with an ePCR-
329 binding *Pf* strain within the first hour of incubation. After 24 hours the system stabilizes and only
330 one miRNA (hsa-miR-451a) was found at higher levels in cell-conditioned media of HBE cells
331 incubated with an ePCR-binding strain compared to cells stimulated with non-adherent (3D7-iE) or
332 non-infected erythrocytes. miR-451 has been implicated in translocation to form a chimera with
333 *Plasmodium* mRNAs to block their translation (34), and also found to be abundant in sickle
334 erythrocytes (35). In addition, it was shown that parasites could reduce miR-451 levels in host
335 fluids (36). However, it was not confirmed in plasmas from Mozambican children in this study.
336 Five miRNA levels were higher in children with SM and severity symptoms (prostration, SA and
337 ARD) compared to UM cases. *Pf* cytoadhesion phenotypes (PM-agglutination and cytoadhesion to
338 gC1qR) were also associated with the differential expression of miRNAs, suggesting that the
339 interaction between PfEMP1 and host receptors leads to the secretion to plasma of specific
340 miRNAs. Moreover, three miRNAs (hsa-miR-10b-5p, hsa-miR-378a-3p and hsa-miR-4497) were
341 positively correlated with HRP2 levels.

342

343 Six candidate miRNAs that were identified in the discovery phase were selected to determine the
344 validity of the previous results in an independent cohort of Mozambican children. The relative
345 expression of hsa-miR-3158-3p and hsa-miR-4497 was significantly higher in children with SM
346 compared to UM, with hsa-miR-3158-3p levels being higher in children with prostration, multiple
347 seizures as well as ARD, and hsa-miR-4497 in children with SA and ARD. To our knowledge, hsa-

348 miR-3158-3p, which is widely expressed in skin, spleen, kidney and brain tissues (37), has been
349 associated with bipolar disorders (38), but not with other infectious diseases. Further validation is
350 required for hsa-miR-3158-3p, as the levels of this miRNA were found to be downregulated in the
351 plasma from Mozambican children recruited in 2006 with positive PM-agglutination compared to
352 no PM-agglutination, a *Pf* cytoadhesion phenotype which has been associated with malaria severity
353 (39). However, the positive correlation of hsa-miR-4497 with HRP2 levels, which was consistently
354 observed in the cohort of children from 2006 and 2014, suggesting that increasing parasite biomass
355 associated with parasite sequestration may lead to higher levels of secretion of this specific miRNA
356 by damaged tissues. hsa-miR-4497 is widely expressed in the lymph nodes, spleen, kidney and liver
357 tissues (37). Overall, this study shows that hsa-miR-4497, which is also associated with SM, might
358 be an interesting proxy marker of malaria severity. However, hsa-miR-4497 was found as a tumour
359 suppressor (40), and associated with *Mycobacterium tuberculosis* infection (41). Therefore,
360 longitudinal studies are required to assess the prognostic value of this miRNA, as well as to
361 estimate its differential expression in children with severity due to non-malarial infections.

362

363 Few of the most expressed miRNAs found in the present study, which represent a 70% of the total
364 miRNA counts in plasma samples, have been reported as highly abundant in plasma samples
365 previously (28, 42). According to public data deposited in the miRmine database (43), hsa-miR-
366 486-5p and hsa-miR-451a are the two most abundant miRNAs in plasma and were also present in
367 the list of ten most expressed miRNAs of this study. Although there is no data available on
368 miRNAs from cell-conditioned media of HBE cells, miRNA data from other cell types, such as
369 primary tissue explants, primary stromal cells and breast cancer cell lines, also show low miRNA
370 yield (44), similar to this study. This observation indicates that RNA sequencing data obtained in
371 this study is of good quality and can be used for posterior analysis with high confidence. However,
372 this study has several limitations. First, only HBE cells and ePCR-binding parasites were utilized

373 for the *in vitro* assay, and therefore miRNAs produced by other parasite-host interactions
374 contributing to SM may have been missed. Second, plasma samples used in this study were
375 collected retrospectively. Therefore, factors prior to small RNA sequencing and TaqMan-RT-
376 qPCRs, such as time taken between centrifugation, storage, and storage temperature, might have
377 varied among the samples, affecting miRNA plasma levels (45, 46). However, confirmation of
378 findings in both the study cohorts suggest a minimal impact of pre-analytical conditions in the
379 results. Third, variations in the number of miRNAs identified in replicates of *in vitro* experiments
380 may have led to the loss of some miRNAs. Fourth, the lack of tissue samples from organs with *Pf*
381 sequestration restricted the histological confirmation of identified miRNAs, and the presence of co-
382 infections other than blood culture positive bacteraemia cannot be neglected in the studied plasma
383 samples. Finally, the association of each miRNA with specific symptoms that are part of the SM
384 case definition may need further validation using a larger sample size, considering that our numbers
385 were relatively small for individual SM criteria. In addition, future studies using the machine-
386 learning approaches would allow the identification of a combination of miRNAs that may detect
387 SM pathologies.

388

389 In conclusion, the profiling of miRNAs in media from HBE cells after incubation with a
390 cytoadherent *Pf* strain and in plasmas from Mozambican children with different clinical
391 presentations allowed the identification of promising miRNA candidates for characterizing severe
392 malaria, specifically hsa-miR-4497. This study opens the ground for future analyses to understand
393 the value of these miRNAs as a prognostic biomarker and for disentangling the aetiology of severe
394 malaria.

395

396

397

398 **Acknowledgements**

399

400 We are grateful to the children who participated in the study; the staff of the Manhiça District
401 Hospital; the clinical officers, field supervisors and data managers; G. Cabrera, L. Mussacate, N.
402 Ernesto José and A. Nhabomba for their contribution to the collection of parasites; L. Puyol for her
403 laboratory management, as well as everyone who supported this study directly or indirectly. We
404 also thank Ruhi Sikka, Varun Sharma, Rebecca Smith-Aguasca, Malia Skjefte, and Catriona
405 Patterson for their useful comments on this manuscript.

406

407 [‡]HG moved to the department of Infection Biology, London School of Hygiene and Tropical
408 Medicine, London, UK.

409

410 This work was supported by the Instituto de Salud Carlos III (PI13/01478 cofunded by the Fondo
411 Europeo de Desarrollo Regional [FEDER], CES10/021-I3SNS to AM and CP11/00269 from the
412 Miguel Servet program to QB). HG was supported (Jan/2017 – Jan/2019) by the Science and
413 Engineering Research Board (SERB), Department of Science & Technology, Government of India
414 (Overseas Postdoctoral Fellowship, SB/OS/PDF-043/2015-16). ISGlobal is a member of the
415 CERCA Programme, Generalitat de Catalunya (<http://cerca.cat/en/suma/>). CISM is supported by
416 the Government of Mozambique and the Spanish Agency for International Development (AECID).
417 This research is part of ISGlobal's Program on the Molecular Mechanisms of Malaria, which is
418 partially supported by the Fundación Ramón Areces.

419

420

421

422

423 **Biographical Sketch**

424

425 Dr. Gupta is a molecular biologist and an early career malaria disease researcher. His research
426 focuses on host and parasite factors associated with severe malaria, and on the use of molecular
427 tools for the active surveillance of emerging drug resistance, gene deletions, and afebrile malaria in
428 malaria-endemic regions.

429

430 **Availability of data and materials**

431

432 The datasets analysed in this study are available from the corresponding author on request.

433

434 **Competing interests**

435

436 The authors declare that they have no competing interests.

437

438 **Authors' contributions**

439

440 HG, MR carried out the molecular analysis, results interpretation and wrote the first draft of this
441 manuscript. PC also carried out molecular analysis and conducted cytoadhesion assays. AS, RV,
442 LM and IC participated in fieldwork, collected clinical, epidemiological data, plasma samples, dried
443 blood drop filter papers and performed microscopy. AJ, XMV and DB participated in HRP2
444 analyse. MR, PC, HG, LP, AB and MB participated in bioinformatics and statistical analyses. QB
445 and AM participated in the study design, supervision, funding acquisition, project administration
446 and coordinated all the stages of the project. All authors reviewed and approved the final
447 manuscript.

448 **References**

449

- 450 1. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al.
451 Artesunate versus quinine in the treatment of severe falciparum malaria in African children
452 (AQUAMAT): an open-label, randomised trial. *Lancet*. 2010 Nov 13;376(9753):1647-57.
- 453 2. Gravenor MB, van Hensbroek MB, Kwiatkowski D. Estimating sequestered parasite
454 population dynamics in cerebral malaria. *Proc Natl Acad Sci U S A*. 1998 Jun 23;95(13):7620-4.
- 455 3. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. *Nature*.
456 2002 Feb 7;415(6872):673-9.
- 457 4. Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, et al. The
458 neuropathology of fatal cerebral malaria in malawian children. *Am J Pathol*. 2011
459 May;178(5):2146-58.
- 460 5. Nagatake T, Hoang VT, Tegoshi T, Rabbege J, Ann TK, Aikawa M. Pathology of
461 falciparum malaria in Vietnam. *Am J Trop Med Hyg*. 1992 Aug;47(2):259-64.
- 462 6. Milner DA, Jr., Whitten RO, Kamiza S, Carr R, Liomba G, Dzamalala C, et al. The systemic
463 pathology of cerebral malaria in African children. *Frontiers in cellular and infection microbiology*.
464 2014;4:104.
- 465 7. White NJ, Turner GD, Day NP, Dondorp AM. Lethal malaria: Marchiafava and Bignami
466 were right. *The Journal of infectious diseases*. 2013 Jul 15;208(2):192-8.
- 467 8. Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of *Plasmodium falciparum*-
468 infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. *Expert*
469 *reviews in molecular medicine*. 2009 May 26;11:e16.
- 470 9. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is
471 associated with parasite binding to endothelial protein C receptor. *Nature*. 2013 Jun
472 27;498(7455):502-5.
- 473 10. Jensen AR, Adams Y, Hviid L. Cerebral *Plasmodium falciparum* malaria: The role of
474 PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. *Immunol*
475 *Rev*. 2020 Jan;293(1):230-52.
- 476 11. Sahu PK, Satpathi S, Behera PK, Mishra SK, Mohanty S, Wassmer SC. Pathogenesis of
477 cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches. *Frontiers in cellular*
478 *and infection microbiology*. 2015;5:75.
- 479 12. Erdman LK, Petes C, Lu Z, Dhabangi A, Musoke C, Cserti-Gazdewich CM, et al. Chitinase
480 3-like 1 is induced by *Plasmodium falciparum* malaria and predicts outcome of cerebral malaria and
481 severe malarial anaemia in a case-control study of African children. *Malaria journal*. 2014 Jul
482 21;13:279.
- 483 13. Lucchi NW, Jain V, Wilson NO, Singh N, Udhayakumar V, Stiles JK. Potential serological
484 biomarkers of cerebral malaria. *Disease markers*. 2011;31(6):327-35.
- 485 14. Tahar R, Albergaria C, Zeghidour N, Ngane VF, Basco LK, Roussilhon C. Plasma levels of
486 eight different mediators and their potential as biomarkers of various clinical malaria conditions in
487 African children. *Malaria journal*. 2016 Jun 29;15:337.
- 488 15. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich
489 K, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2.
490 *PLoS medicine*. 2005 Aug;2(8):e204.
- 491 16. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R,
492 et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective
493 evaluation of plasma PfHRP2 measurement. *PLoS medicine*. 2012;9(8):e1001297.

- 494 17. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA.
495 MicroRNAs in body fluids--the mix of hormones and biomarkers. *Nat Rev Clin Oncol*. 2011
496 Aug;8(8):467-77.
- 497 18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al.
498 Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S*
499 *A*. 2008 Jul 29;105(30):10513-8.
- 500 19. Hakimi MA, Cannella D. Apicomplexan parasites and subversion of the host cell microRNA
501 pathway. *Trends in parasitology*. 2011 Nov;27(11):481-6.
- 502 20. El-Assaad F, Hempel C, Combes V, Mitchell AJ, Ball HJ, Kurtzhals JA, et al. Differential
503 microRNA expression in experimental cerebral and noncerebral malaria. *Infect Immun*. 2011
504 Jun;79(6):2379-84.
- 505 21. Baro B, Deroost K, Raiol T, Brito M, Almeida AC, de Menezes-Neto A, et al. Plasmodium
506 vivax gametocytes in the bone marrow of an acute malaria patient and changes in the erythroid
507 miRNA profile. *PLoS neglected tropical diseases*. 2017 Apr;11(4):e0005365.
- 508 22. Xue X, Zhang Q, Huang Y, Feng L, Pan W. No miRNA were found in Plasmodium and the
509 ones identified in erythrocytes could not be correlated with infection. *Malaria journal*. 2008 Mar
510 10;7:47.
- 511 23. Rubio M, Bassat Q, Estivill X, Mayor A. Tying malaria and microRNAs: from the biology
512 to future diagnostic perspectives. *Malaria journal*. 2016 Mar 15;15:167.
- 513 24. Spearman's correlation. [cited; Available from:
514 <http://www.statstutor.ac.uk/resources/uploaded/spearmans.pdf>
- 515 25. Mayor A, Serra-Casas E, Bardaji A, Sanz S, Puyol L, Cistero P, et al. Sub-microscopic
516 infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant
517 women. *Malar J*. 2009 Jan 9;8:9.
- 518 26. Taylor SM, Mayor A, Mombo-Ngoma G, Kenguele HM, Ouedraogo S, Ndam NT, et al. A
519 quality control program within a clinical trial Consortium for PCR protocols to detect Plasmodium
520 species. *Journal of clinical microbiology*. 2014 Jun;52(6):2144-9.
- 521 27. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzese JL, et al. MicroRNAs in plasma of
522 pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. *Cancer*
523 *prevention research*. 2009 Sep;2(9):807-13.
- 524 28. Rubio M, Bustamante M, Hernandez-Ferrer C, Fernandez-Orth D, Pantano L, Sarria Y, et al.
525 Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk. *PLoS*
526 *One*. 2018;13(3):e0193527.
- 527 29. Pantano L, Estivill X, Marti E. SeqBuster, a bioinformatic tool for the processing and
528 analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic
529 cells. *Nucleic acids research*. 2010 Mar;38(5):e34.
- 530 30. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
531 RNA-seq data with DESeq2. *Genome biology*. 2014;15(12):550.
- 532 31. Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL. Normalization of
533 circulating microRNA expression data obtained by quantitative real-time RT-PCR. *Briefings in*
534 *bioinformatics*. 2016 Mar;17(2):204-12.
- 535 32. Pantano L, Estivill X, Marti E. A non-biased framework for the annotation and classification
536 of the non-miRNA small RNA transcriptome. *Bioinformatics*. 2011 Nov 15;27(22):3202-3.
- 537 33. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G. The Impact of
538 Hemolysis on Cell-Free microRNA Biomarkers. *Frontiers in genetics*. 2013;4:94.
- 539 34. LaMonte G, Philip N, Reardon J, Lacsina JR, Majoros W, Chapman L, et al. Translocation
540 of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and
541 contributes to malaria resistance. *Cell host & microbe*. 2012 Aug 16;12(2):187-99.

- 542 35. Chen SY, Wang Y, Telen MJ, Chi JT. The genomic analysis of erythrocyte microRNA
543 expression in sickle cell diseases. *PLoS One*. 2008 Jun 4;3(6):e2360.
- 544 36. Rathjen T, Nicol C, McConkey G, Dalmay T. Analysis of short RNAs in the malaria
545 parasite and its red blood cell host. *FEBS Lett*. 2006 Oct 2;580(22):5185-8.
- 546 37. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of
547 miRNA expression across human tissues. *Nucleic acids research*. 2016 May 5;44(8):3865-77.
- 548 38. Maffioletti E, Cattaneo A, Rosso G, Maina G, Maj C, Gennarelli M, et al. Peripheral whole
549 blood microRNA alterations in major depression and bipolar disorder. *Journal of affective
550 disorders*. 2016 Aug;200:250-8.
- 551 39. Mayor A, Hafiz A, Bassat Q, Rovira-Vallbona E, Sanz S, Machevo S, et al. Association of
552 severe malaria outcomes with platelet-mediated clumping and adhesion to a novel host receptor.
553 *PLoS One*. 2011 Apr 29;6(4):e19422.
- 554 40. Chen X, Zhang L, Tang S. MicroRNA-4497 functions as a tumor suppressor in laryngeal
555 squamous cell carcinoma via negatively modulation the GBX2. *Auris Nasus Larynx*. 2019
556 Feb;46(1):106-13.
- 557 41. Das K, Saikolappan S, Dhandayuthapani S. Differential expression of miRNAs by
558 macrophages infected with virulent and avirulent *Mycobacterium tuberculosis*. *Tuberculosis*. 2013
559 Dec;93 Suppl:S47-50.
- 560 42. Tonge DP, Gant TW. What is normal? Next generation sequencing-driven analysis of the
561 human circulating miRNAome. *BMC molecular biology*. 2016 Feb 9;17:4.
- 562 43. Panwar B, Omenn GS, Guan Y. miRmine: a database of human miRNA expression profiles.
563 *Bioinformatics*. 2017 May 15;33(10):1554-60.
- 564 44. Glynn CL, Khan S, Kerin MJ, Dwyer RM. Isolation of secreted microRNAs (miRNAs) from
565 cell-conditioned media. *MicroRNA*. 2013;2(1):14-9.
- 566 45. Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, et al. Stability of
567 Circulating Blood-Based MicroRNAs - Pre-Analytic Methodological Considerations. *PLoS One*.
568 2017;12(2):e0167969.
- 569 46. Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma:
570 effect of preanalytical and analytical parameters on their isolation and stability. *The Journal of
571 molecular diagnostics : JMD*. 2013 Nov;15(6):827-34.

572

573

574

575

576


577

578

579

580

581 **Figure 1: Schematic representation of the study design to identify miRNA based biomarkers**
582 **of severe malaria.** [ePCR: endothelial protein-C receptor (a binding *P. falciparum* strain-FCR3);
583 3D7: a non-binding *P. falciparum* strain; iE: infected erythrocyte; niE: non-infected erythrocyte;
584 HRP2: Histidine-rich protein 2].



585

586

587

588

589

590

591

592

593


594

595

596 **Figure 2: RNA sequencing of human brain endothelial (HBE) cell media and plasma from**
597 **Mozambican children recruited in 2006.**

598

599 **A)** Percentage of mapped reads in different species of small RNAs, for both *in vitro* and *ex vivo*
600 approaches. **B)** Ten most expressed miRNAs in HBE cell medias and plasmas. Colour coded cells
601 show the percentage of each assay/condition (columns) for each miRNA (rows). Volcano plot of
602 differentially expressed miRNAs in **C)** cell-condition media of non-infected erythrocytes (niE)
603 versus cell-condition media of infected erythrocytes with the FCR3-ePCR strain (ePCR-iE)
604 incubated with HBE cells and **D)** cell-condition media of infected erythrocytes with 3D7 strain
605 (3D7-iE) versus cell-condition media of infected erythrocytes with the FCR3-ePCR strain (ePCR-
606 iE) incubated with HBE cells. Both comparisons (C and D) were adjusted for multiple testing by the
607 Benjamini-Hochberg method. Negative log₂FoldChanges indicates overexpression in ePCR-iE
608 samples. (SM: severe malaria; UM: uncomplicated malaria).




609

610 **Figure 3: Spearman correlations between HRP2 levels and miRNA relative expression levels**
611 **(RELs) in plasma samples from Mozambican children recruited in 2006.**

612

613 HRP2 levels and miRNA RELs were log transformed. The correlation analysis was adjusted for

614 multiple testing by the Benjamini-Hochberg method.



615

616

617

618

619

620

621

622

623

624

625

626

627


628

629

630 **Figure 4: miRNA validation in plasma samples of Mozambican children recruited in 2014.**

631

632 Relative expression levels (RELs) were calculated with respect to the mean of two endogenous
633 controls (hsa-miR-30d-5p and hsa-miR-191-5p) and compared between children with severe
634 malaria (SM) and uncomplicated malaria (UM). Statistical differences were obtained from Mann-
635 Whitney U test. T bars represent median and Interquartile Ranges (IQR).



636

637

638

639

640

641

642

643

644 **Figure 5: Association of miRNA levels with symptoms of severity.**

645

646 Relative expression levels (RELs) were calculated with respect to the mean of two endogenous


647 controls (hsa-miR-30d-5p and hsa-miR-191-5p) and compared between children with

648 uncomplicated malaria (UM) and symptoms of severity. Distributions were compared using Mann-

649 Whitney U test. T bars represent median and Interquartile Ranges (IQR). P values are shown for

650 significant comparisons. [Prostration (P), Multiple seizures (MS), Acidosis or acute respiratory

651 distress (ARD), Severe anaemia (SA)].



652

653


654

655

656

657

658 **Figure 6: Spearman correlations between HRP2 levels and miRNA relative expression levels**
659 **(RELs) in plasma samples from Mozambican children recruited in 2014. HRP2 levels and**
660 **miRNA RELs were log transformed.**



661

662

663

664

665

666

667

668

669

670

671

672

19th Dec

Gupta et al

673 **Table 1:** Quality control and mapped reads (mean and standard deviations) in different species of small
674 RNAs obtained from cell-conditioned media of human brain endothelial cells exposed to cytoadherent *P.*
675 *falciparum* infected and non-infected erythrocytes, and plasma of Mozambican children with severe and
676 uncomplicated malaria.

| | Condition | | | | | | | |
|----------------------------------|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|------------------|------------------|
| | niE | | 3D7-iE | | ePCR-iE | | UM | SM |
| | t1 (N=3) | t24 (N=3) | t1 (N=3) | t24 (N=3) | t1 (N=3) | t24 (N=3) | (N=39) | (N=44) |
| Total reads, millions (SD) | 8.70 (3.55) | 16.71 (14.59) | 10.43 (3.48) | 25.86 (28.14) | 4.78 (2.13) | 6.11 (1.18) | 10.90 (9.69) | 9.26 (6.06) |
| Quality filtered, counts (SD) | 46.00 (36.72) | 33.33 (29.67) | 14.67 (23.69) | 125.67 (217.66) | 10.67 (2.31) | 16.33 (25.70) | 557.62 (1200.76) | 615.75 (1163.62) |
| Complexity filtered, counts (SD) | 910.67 (775.48) | 745.00 (659.60) | 369.33 (567.40) | 3168.67 (5438.11) | 220.67 (163.57) | 308.00 (526.55) | 535.97 (884.46) | 506.23 (455.16) |
| Size filtered, millions (SD) | 0.63 (0.34) | 2.26 (2.99) | 0.68 (0.40) | 2.12 (2.92) | 0.90 (0.48) | 0.49 (0.50) | 1.94 (1.51) | 2.39 (1.82) |
| Good quality reads* | | | | | | | | |
| Millions (SD) | 8.07 (3.35) | 14.44 (11.60) | 9.75 (3.10) | 23.74 (25.23) | 3.88 (2.00) | 5.62 (0.84) | 8.96 (8.89) | 6.88 (4.64) |
| Percentage (SD) | 92.62 (2.54) | 90.35 (6.98) | 93.93 (2.37) | 94.15 (3.26) | 79.60 (8.86) | 92.62 (6.35) | 77.76 (15.31) | 74.95 (11.08) |
| miRNA | | | | | | | | |
| Millions (SD) | 0.26 (0.19) | 1.09 (1.57) | 0.27 (0.19) | 0.98 (1.14) | 0.25 (0.07) | 0.15 (0.13) | 2.05 (2.50) | 1.33 (1.42) |
| Percentage (SD) | 3.02 (1.73) | 4.97 (4.92) | 2.47 (1.52) | 3.75 (0.54) | 7.41 (3.44) | 2.47 (1.97) | 22.43 (16.01) | 20.21 (13.22) |
| rRNA | | | | | | | | |
| Millions (SD) | 2.34 (1.82) | 3.12 (2.71) | 1.57 (1.72) | 5.74 (9.19) | 0.72 (0.38) | 0.90 (1.08) | 0.92 (0.97) | 0.81 (0.72) |
| Percentage (SD) | 24.72 (16.01) | 20.36 (14.62) | 14.84 (15.37) | 13.41 (15.42) | 19.55 (5.14) | 15.13 (16.99) | 11.11 (7.75) | 11.49 (5.78) |
| tRNA | | | | | | | | |
| Millions (SD) | 1.72 (0.58) | 3.37 (1.51) | 3.75 (1.80) | 6.35 (3.00) | 0.84 (0.64) | 2.47 (1.47) | 1.13 (1.17) | 1.14 (0.94) |
| Percentage (SD) | 27.51 (23.37) | 32.53 (27.16) | 41.04 (20.74) | 43.47 (23.59) | 18.65 (9.43) | 45.24 (26.80) | 13.93 (6.85) | 17.79 (7.70) |
| Unknown | | | | | | | | |
| Millions (SD) | 3.75 (1.92) | 6.86 (6.80) | 4.16 (1.67) | 10.66 (12.55) | 2.07 (0.97) | 2.11 (0.67) | 4.87 (5.88) | 3.59 (2.62) |
| Percentage (SD) | 44.76 (6.35) | 42.14 (11.63) | 41.65 (5.12) | 39.37 (8.36) | 54.40 (3.75) | 37.15 (7.89) | 52.53 (16.01) | 50.51 (13.55) |

677 *Reads after filtering low quality, low complexity and short (<18nt) sequences

678 SM, Severe malaria; UM, Uncomplicated malaria; niE, non-infected erythrocytes; 3D7-iE, non-adherent 3D7-infected erythrocytes;
679 ePCR-iE, adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes; three replicates of the media collected from
680 each cytoadhesion assay after one (t1) and 24 hours (t24)

681

682

683

684

685

686

687

688 **Table 2:** Characteristics of Mozambican children with severe and uncomplicated malaria recruited in 2006
689 (discovery) and 2014 (validation).

| | 2006 | | | 2014 | | |
|---|-------------------|--------------------|---------|---------------------|---------------------|---------|
| | UM N=39 | SM N=44 | p value | UM N=30 | SM N=40 | p value |
| Age [#] (year), mean (SD) | 2.3 (1.1) | 2.4 (1.3) | 0.671 | 2.2 (1.3) | 2.8 (1.2) | 0.419 |
| Sex, n (%) | | | | | | |
| Men | 24 (62) | 28 (64) | 1.000 | 18 (60) | 21 (52.5) | 0.532 |
| Women | 15 (38) | 16 (36) | | 12 (40) | 19 (47.5) | |
| HRP2 (ng/ml), GM (SD) | 71.3 (10.7) | 331.4 (40.7) | <0.001 | 24.1 (4.9) | 78.7 (12.2) | 0.038 |
| qPCR (parasites/μl), GM (SD) | 2084.9 (302.5) | 7976.1 (1079.6) | 0.004 | 72845.9 (7193.9) | 94099.6 (8716.0) | 0.549 |
| Splenomegaly, n (%) | | | | | | |
| No | 33 (85) | 21 (48) | 0.001 | ND | 27 (67.5) | NA |
| Yes | 6 (15) | 23 (52) | | ND | 13 (32.5) | |
| Hepatomegaly, n (%) | | | | | | |
| No | 38 (97) | 35 (80) | 0.016 | ND | 35 (87.5) | NA |
| Yes | 1 (3) | 9 (20) | | ND | 5 (12.5) | |
| Hyperlactatemia, n (%) | | | | | | |
| No | 10 (26) | 5 (11) | 0.152 | 26 (86.7) | 27 (67.5) | 0.064 |
| Yes | 29 (74) | 39 (89) | | 4 (13.3) | 13 (32.5) | |
| Temperature (°C), mean (SD) | 38.0 (1.6) | 38.5 (1.1) | 0.093 | 38.0 (1.3) | 38.2 (1.4) | 0.437 |
| Weight (Kg), mean (SD) | 11.3 (2.8) | 11.0 (2.8) | 0.599 | 12.3 (2.9) | 12.7 (3.3) | 0.476 |
| Platelets (10 ⁹ /L), mean (SD) | 156.7 (86.8) | 115.8 (66.8) | 0.018 | 149.0 (89.7) | 95.3 (69.3) | 0.001 |
| Glucose ^a (mM), mean (SD) | 6.2 (1.5) | 5.9 (1.8) | 0.391 | 6.6 (1.3) | 6.0 (2.6) | 0.165 |
| WBC (10 ⁹ /L), mean (SD) | 9.9 (4.1) | 10.2 (3.9) | 0.774 | 9.7 (3.8) | 9.6 (5.0) | 0.929 |
| Neutrophils ^c (%), mean (SD) | 54.1 (16.7) | 54.4 (14.3) | 0.940 | 50.7 (20.6) | 58.9 (13.7) | 0.447 |
| Lymphocytes ^d (%), mean (SD) | 39.4 (17.9) | 36.3 (12.6) | 0.374 | 26.1 (17.1) | 25.6 (12.2) | 0.995 |
| Lactate (mM), mean (SD) | 3.0 (1.7) | 4.7 (3.6) | 0.009 | 2.8 (2.2) | 3.6 (2.4) | 0.035 |
| Severe malaria syndromes, n (%) | | | | | | |
| Prostration | | 33 (75.0) | | | 30 (75.0) | |
| Acute respiratory distress | | 18 (40.9) | | | 19 (47.5) | |
| Severe anaemia | | 17 (38.6) | | | 7 (17.5) | |
| Multiple seizures | | 11 (25.0) | | | 24 (60.0) | |
| Cerebral malaria | | 2 (4.5) | | | 7 (17.5) | |
| Hypoglycaemia | | 2 (4.5) | | | 2 (5.0) | |

690 Continuous data = Mann Whitney test; categorical data = Chi-square test
691 SM, Severe malaria; UM, Uncomplicated malaria; HRP2, Histidine-rich protein 2; WBC, White blood cells; GM, Geometric mean; SD,
692 Standard deviation; ND, not determined; NA, not applicable
693 [#] No data of 1 sample (UM=1) in 2014 study
694 ^a No data of 3 sample (SM=2; UM=1) in 2014 study
695 ^c No data of 4 samples (SM=4) in 2014 study
696 ^d No data of 3 samples (SM=3) in 2014 study

697

698

699

700

701

702

703

704

705

706

707 **Table 3:** Association of miRNA levels with severe malaria, symptoms of severity and *Plasmodium falciparum*
708 cytoadhesion. Positive FoldChange indicates overexpression in severe malaria and symptoms of severity
709 compared to uncomplicated malaria as well as parasites showing cytoadhesion compared to none.

710

| miRNA | baseMean | log2FoldChange | padj |
|--|----------|----------------|--------|
| Clinical data | | | |
| Severe malaria (N=44 vs 39) | | | |
| hsa-miR-122-5p | 19929.69 | 1.67 | 0.001 |
| Severe anaemia (N=17 vs 39) | | | |
| hsa-miR-4492 | 17.34 | 2.81 | 0.046 |
| hsa-miR-4497 | 293.66 | 2.18 | 0.046 |
| Prostration (N=33 vs 39) | | | |
| hsa-miR-122-5p | 20677 | 1.89 | 0.001 |
| hsa-miR-6087 | 5.36 | 2.39 | 0.033 |
| hsa-miR-511-5p | 126.67 | 1.36 | 0.040 |
| Acidosis or respiratory distress (N=18 vs 39) | | | |
| hsa-miR-122-5p | 13367.43 | 2.21 | <0.001 |
| hsa-miR-4497 | 272.39 | 2.05 | 0.07 |
| Cytoadhesion data | | | |
| Platelet-mediated agglutination (N=50 vs 19) | | | |
| hsa-miR-3158-3p | 1180.96 | -2.26 | <0.001 |
| hsa-miR-320a | 22005.69 | -1.48 | 0.001 |
| hsa-miR-4492 | 18.33 | 2.78 | 0.002 |
| hsa-miR-1290 | 1011.34 | -1.38 | 0.014 |
| hsa-miR-320b | 1191.44 | -1.23 | 0.014 |
| hsa-miR-320c | 408.32 | -1.29 | 0.014 |
| hsa-miR-1246 | 3907.45 | -1.32 | 0.019 |
| hsa-miR-6741-5p | 48.11 | -1.81 | 0.023 |
| hsa-miR-1228-5p | 82.73 | -1.88 | 0.023 |
| hsa-miR-3195 | 16.35 | 2.21 | 0.023 |
| hsa-miR-7706 | 334.86 | -1.00 | 0.023 |
| gC1qR (N=35 vs 34) | | | |
| hsa-miR-1-3p | 622.35 | 2.09 | 0.003 |

711

712

713

714

715

716

717

718

719

Total number of miRNAs were 1450 in RNA sequencing data;
baseMean = Mean normalized expression of the miRNAs in all the samples;
padj = adjusted for multiple testing by the Benjamini-Hochberg method

720 **Technical Appendix**

721

722 **Material and Methods**

723

724 **Study population**

725

726 Clinical malaria was defined as the presence of fever (axillary temperature $\geq 37.5^{\circ}\text{C}$) with an asexual
727 parasitemia of $Pf \geq 500/\mu\text{L}$. Children with severe malaria (SM) were those with at least one of the
728 following symptoms: cerebral malaria (Blantyre Coma Score ≤ 2), severe anaemia (SA, packed cell
729 volume $< 15\%$ or haemoglobin $< 5\text{g/dL}$), acidosis or acute respiratory distress (ARD, lactate $> 5\text{mM}$
730 and/or chest in-drawing or deep breathing), prostration (inability to sit or breastfeed in children old
731 enough to do so based on their age), hypoglycaemia (blood glucose $< 2.2\text{mM}$) and multiple seizures
732 (≥ 2 convulsions in the preceding 24h) following the modified WHO criteria (1). Children with
733 uncomplicated malaria (UM) were those with clinical malaria but not presenting any
734 signs/symptoms of severity mentioned above (2). The presence of concomitant bacteraemia was
735 tested in all SM cases using blood cultures and children with positive bacteraemia were excluded.
736 Children with SM were treated according to Mozambican national guidelines with parenteral
737 quinine in 2006 or parenteral artesunate (complemented with an oral artemisinin-based combination
738 therapy) in 2014, and those with UM were treated with a combination of oral amodiaquine and
739 sulfadoxine-pyrimethamine (Fansidar[®]) in 2006 or with artemether-lumefantrine (Coartem[®]) in
740 2014. Ten ml of heparinized blood was collected from study participants and processed within 2
741 hours after collection. Filter paper dried blood spots of $60\mu\text{L}$ blood were prepared from the
742 vacutainer blood. After centrifugation at 1000rpms for 10minutes at 4°C , plasma was stored at -
743 20°C . The 2014 study was conducted as a quasi-exact repetition of the 2006 study, the only

744 difference being that cases and controls were matched by parasitaemia level. Biochemistry
745 parameters (glucose and lactate) and a full blood count were performed for each patient using
746 Vitros DT60 and Sysmex Kx21 analyzers, respectively.

747

748 **Parasitological determinations**

749

750 Histidine-rich protein 2 (HRP2) levels were quantified using commercially available enzyme-linked
751 immunosorbent assay kits (Malaria Ag CELISA; Cellabs Pty. Ltd., Brookvale, New South Wales,
752 Australia) and an in-house highly sensitive quantitative bead suspension array based on Luminex
753 technology. In brief, plasma samples were incubated overnight at 4°C with 2000 magnetic beads to
754 a final dilution of 1:10. After washing, beads were sequentially incubated with 100 µL of in-house
755 biotinylated antibody α -HRP2 (MBS832975, MyBioSource, San Diego, CA) at 1 µg/ml and with
756 streptavidin-PE (42250-1ML, Sigma Aldrich, St. Louis, MO) at 1:1000 dilution. Finally, beads
757 were washed and re-suspended in assay buffer, and the plate was read using the Luminex xMAP®
758 100/200 analyser (Luminex Corp., Austin, TX). A minimum of 50 microspheres per analyte were
759 acquired and results were exported as crude median fluorescent intensity (MFI). Background
760 (blank) MFIs were subtracted and normalized to account for plate to plate variation. Quantification
761 was performed against a 5-parameter logistic regression curve fitted from a calibration curve
762 consisting of recombinant protein HRP2 type A (890015, Microcoat GmbH, Germany).

763

764 ***Pf* cytoadhesion assays**

765

766 Human brain microvascular endothelial cells (Innoprot, Reference P10361) were cultured in 12
767 well-plates following the supplier's recommendations and were left until 40% confluency was
768 achieved. HBE cells were incubated in triplicate with *Pf*-iEs at trophozoite stage of the ePCR-

769 binding FCR3 strain (ePCR-iE; which expresses the PfEPM1 protein that binds to ePCR receptor)
770 and 3D7 strain (3D7-iE; a strain without the protein that binds to ePCR receptor) with 5% of both
771 parasitemia and haematocrit. Non-infected erythrocytes were used as negative control. The cell-
772 conditioned media of each group were collected after 1hr (t1) and 24hrs of stimulation (t24). Next
773 day, HBE cells were stimulated as described above, after 1-hour incubation in agitation, cells were
774 washed at least 10 times with binding media and fixed with 2% glutaraldehyde (SIGMA) in PBS
775 (Gibco) overnight to assess adhesion by light microscopy. After washing with water, cells were
776 stained with 10% Giemsa. iE and niE bound were counted in six different wells per assay in at least
777 500 nuclei cell per well. Results were presented as the number of adhered iE per 500 nuclei of cells.
778 Estimation of *Pf* adhesion to purified receptors (CD36, CD54 and g1CqR) as well as platelet-
779 mediated (PM)-agglutination and rosetting was performed as described elsewhere (2, 3).
780 Cytoadherence was defined as positive only if the number of iEs bound per mm² was greater than
781 the mean binding plus 2 standard deviations to Duffy-Fc coated petri dishes. *Pf* isolates were
782 considered positive for PM clumping if the frequency of clumps was higher in the presence of
783 platelets than in buffer-control and for rosetting if the frequency of rosettes was higher than 2% (2,
784 4).

785

786 **Small RNA sequencing**

787

788 Before RNA extraction, the level of haemolysis in plasma samples was assessed by
789 spectrophotometry (EPOCH, BioTek) at a wavelength of 414nm (absorbance peak of free
790 haemoglobin). Samples were classified as non-haemolysed if the optical density at 414nm was less
791 than 0.2 (5). RNA was extracted from cell-conditioned media (3ml) and plasma samples (1ml)
792 using the miRNeasy tissues/cells kit and miRNeasy Plasma/Serum kit (Qiagen), respectively, with
793 the use of 5µg UltraPure™ glycogen/sample (Invitrogen). Given that the plasma samples were

794 conserved in heparin, RNA was precipitated with LiCl as described elsewhere (6). Purified RNA
795 quality and quantity were determined using the Bioanalyzer (Agilent Technologies) followed by
796 preparation of libraries using NEBNext® Small RNA Library Prep Set for Illumina® (New
797 England Biolabs), then separation of libraries in polyacrylamide gels (Novex, Invitrogen). The
798 Bioanalyzer was again used to quantify and assess the size of the libraries. Further, libraries were
799 pooled at the same equimolar concentrations and no more than 18 libraries were sequenced in the
800 same lane using a HiSeq 2000 (Illumina) platform following the protocol for small RNAs (7).

801

802 A previously published pipeline was used to assess the sequencing quality, identification and
803 quantification of small RNAs and normalization (7). First, a quality control (QC) was conducted
804 using FASTX-Toolkit and FastQ Screen. After adaptor removing, reads with the following features
805 were removed: 1) Reads <18nt, 2) Mean PHRED scores <30 and 3) Low complexity reads based on
806 the mean score of the read. Good quality reads were then annotated to main RNA categories (tRNA,
807 rRNA and miRNAs), and miRNA complexity was estimated as the number of distinct miRNAs that
808 were observed in each sample. Finally, contamination with RNA from other species was evaluated
809 by mapping reads to clade-specific mature miRNA sequences extracted from miRBase v21 (8). The
810 tested species categories include animal sponges, nematodes, insects, lophotrochozoan,
811 echinoderms, fish, birds, reptiles, rodents and primates.

812

813 Sequences that passed the QC were subjected to the seqBuster/seqCluster tool that retrieves miRNA
814 and isomiRs counts (9, 10). To detect miRNAs and isomiRs, reads were mapped to the precursors
815 and annotated to miRNAs or isomiRs using miRBase version 21 with the miraligner (9). DESeq2 R
816 package v.1.10.1 (R version 3.3.2) (11) was used to perform an internal normalization where the
817 counts for a miRNA in each sample were divided by the median of the ratios of observed counts to
818 the geometric mean of each corresponding miRNAs over all samples.

819

820 **Reverse transcriptase quantitative PCR**

821

822 Fifty μ l of plasma from the Mozambican children recruited in 2014 with no haemolysis were used
823 for RNA extraction as described above. A synthetic RNA mimicking ath-miR-159a (*Arabidopsis*
824 *thaliana*; Metabion) was added after lysis reaction at a final concentration of 1.5pM. cDNA
825 synthesis and RT-qPCR [ABI PRISM 7500 HT Real-Time System (Applied Biosystems, Foster
826 City, USA)] were performed using the TaqMan[®] Advanced miRNA assays. A standard curve of
827 five serially diluted points was prepared with cDNA of six randomly selected samples and was run
828 in triplicate for each miRNA. Results were normalized using a combination of endogenous controls
829 (ECs). The selection of ECs was based on the following criteria: a) reported in scientific literature
830 as previously used as ECs (12, 13), b) coefficient of variance (CV) of normalized counts across all
831 samples $\leq 5\%$, c) basemean ≥ 3000 , d) standard deviation ≤ 1 and e) \log_2 fold change between SM and
832 UM patients ≤ 1 . Finally, the best two ECs tested as housekeepings using the NormFinder (14) were
833 used for normalization of RT-qPCR data. miRNA relative expression levels (RELs) were calculated
834 with the $2^{-\Delta Ct}$ method, where $\Delta Ct = [Ct(\text{miRNA}) - \text{Mean Ct}(\text{ECs})]$, considering efficiencies of
835 100% for all the miRNAs and ECs (12).

836

837 ***In silico* analysis**

838

839 The selected miRNAs were screened through four different gene target prediction programs:
840 DIANA-microT-CDS (15), MiRDIP (16), MirGate (17), and TargetScan
841 (http://www.targetscan.org/vert_71/). Identified gene targets of each program were compared using
842 an online tool Venny2.1.0 (<http://bioinfogp.cnb.csic.es/tools/venny/>). The gene targets that occurred
843 in more than one database were selected and screened through the miRTarBase (18) online program

844 to check if these genes have been experimentally validated previously. These gene targets were
845 anticipated to be true positive targets present at detectable levels in field samples. The identified
846 gene targets were further analysed by DAVID 6.8 using *Homo sapiens* as the reference species.
847 Genes were clustered to Gene Ontology terms and KEGG pathways (fold enrichment >1.5 and p
848 <0.05).

849

850 **Statistical analysis**

851

852 Differential expression of miRNAs and isomiRs was assessed using DESeq2 and IsomiRs packages
853 in R (9, 10), which use negative binomial generalized linear models adjusted for multiple testing
854 with the false discovery rate (FDR) by the Benjamini-Hochberg method (19). Those with an FDR
855 of 5% or below were selected for posterior analysis. Analysis of the modification in the bases of the
856 seed region was carried using isomiR package to determine a possible change in the target
857 messenger RNAs. Mann-Whitney U and χ^2 (Chi-square) tests were performed to compare
858 continuous data and categorical data, respectively. Spearman correlation analysis was performed to
859 assess the correlation of miRNA RELs (log transformed) with log transformed HRP2 levels. A two-
860 sided p<0.05 was considered statistically significant. All statistical analyses were performed using
861 R 3.3.2 in Linux-based system and graphs were prepared with GraphPad.

862

863

864


865

866

867

868 **Figure 1: Cytoadhesion assay:** Infected erythrocytes (iEs) with human brain endothelial (HBE)
869 cells stained with Giemsa and visualised at 200X. A) non-infected erythrocytes (niE), B) non-
870 adherent 3D7-infected erythrocytes (3D7-iE), C) adherent FCR3 expression endothelial receptor of
871 protein C-infected erythrocytes (ePCR-iE) and D) three group's comparison for infected
872 erythrocytes adhered to HBE cells. Bars represent the mean and T line the standard deviation. p
873 values were calculated using an unpaired t-test.


874



875

876

877 **Figure 2: RT-qPCR Ct values of exogenous (ath-miR-159a) and endogenous (hsa-miR-191-5p,**
878 **hsa-miR-30d-5p and hsa-miR-148a-3p) controls in severe malaria (SM) and uncomplicated**
879 **malaria (UM) groups. Distributions were compared using Mann-Whitney U test. T bars represent**
880 **median and Interquartile Ranges (IQR).**



881

882

883

884

885

886 **Table 1:** Number of reads, quality control and number of different miRNAs detected in cell-
887 conditioned media of human brain endothelial cells exposed to cytoadherent (ePCR-iE), non-
888 cytoadherent (3D7-iE) *P. falciparum* infected and non-infected erythrocytes (niE).

889

| Sample | Total reads | Quality filtered | Complexity filtered | Length filtered | Good quality reads | rRNA | tRNA | miRNA | Unknown | Different miRNAs |
|---------------|-------------|------------------|---------------------|-----------------|--------------------|----------|---------|---------|----------|------------------|
| t1_niE-1 | 4681945 | 4 | 34 | 337979 | 4343966 | 270763 | 2366921 | 75187 | 1631095 | 231 |
| t1_niE-2 | 11411515 | 62 | 1191 | 562570 | 10848945 | 3679590 | 1543964 | 252710 | 5372681 | 212 |
| t1_niE-3 | 10012344 | 72 | 1507 | 1000811 | 9011533 | 3064588 | 1243462 | 449402 | 4254081 | 465 |
| t1_3D7-iE-1 | 12991483 | 2 | 81 | 850480 | 12141003 | 912334 | 5575569 | 369947 | 5283153 | 233 |
| t1_3D7-iE-2 | 6470351 | 0 | 4 | 225621 | 6244730 | 281177 | 3677882 | 46237 | 2239434 | 240 |
| t1_3D7-iE-3 | 11824305 | 42 | 1023 | 965079 | 10859226 | 3529982 | 1986414 | 392862 | 4949968 | 256 |
| t1_ePCR-iE-1 | 5571743 | 8 | 60 | 1450083 | 4121660 | 585628 | 982702 | 215775 | 2337555 | 363 |
| t1_ePCR-iE-2 | 2366064 | 12 | 215 | 591454 | 1774610 | 434035 | 137804 | 201756 | 1001015 | 122 |
| t1_ePCR-iE-3 | 6400097 | 12 | 387 | 651993 | 5748104 | 1148564 | 1398684 | 322921 | 2877935 | 181 |
| t24_niE-1 | 33411780 | 61 | 1326 | 5688689 | 27723091 | 5762892 | 4456704 | 2896826 | 14606669 | 157 |
| t24_niE-2 | 10227177 | 37 | 881 | 899113 | 9328064 | 3242238 | 1646379 | 328760 | 4110687 | 137 |
| t24_niE-3 | 6482702 | 2 | 28 | 203593 | 6279109 | 347523 | 4011059 | 58043 | 1862484 | 119 |
| t24_3D7-iE-1 | 14668936 | 0 | 51 | 730638 | 13938298 | 663276 | 7270210 | 498805 | 5506007 | 101 |
| t24_3D7-iE-2 | 5034919 | 0 | 7 | 156980 | 4877939 | 208106 | 2998788 | 161344 | 1509701 | 146 |
| t24_3D7-iE-3 | 57868438 | 377 | 9448 | 5474274 | 52394164 | 16356374 | 8786690 | 2280235 | 24970865 | 230 |
| t24_ePCR-iE-1 | 6163503 | 2 | 2 | 156258 | 6007245 | 212547 | 3808455 | 92989 | 1893254 | 120 |
| t24_ePCR-iE-2 | 7262082 | 46 | 916 | 1057919 | 6204163 | 2149075 | 896948 | 293743 | 2864397 | 223 |
| t24_ePCR-iE-3 | 4907246 | 1 | 6 | 246902 | 4660344 | 336305 | 2697248 | 52875 | 1573916 | 118 |

890

891

892

893

894

895 **Table 2:** miRNAs differentially expressed in cell-conditioned media of human brain endothelial
896 cells when exposed to niE and compared with ePCR-iE after one hour incubation. Positive
897 FoldChange indicates overexpression in niE.

898

| miRNA | baseMean | log2FoldChange | padj |
|-----------------|-------------|----------------|----------|
| hsa-miR-150-5p | 3628.925319 | 7.106957417 | 2.20E-64 |
| hsa-miR-1246 | 8513.8312 | 6.854156394 | 2.86E-33 |
| hsa-miR-342-3p | 663.0033186 | 5.589928255 | 2.74E-29 |
| hsa-miR-1290 | 958.7797602 | 6.480019242 | 3.64E-22 |
| hsa-miR-223-5p | 359.7886812 | 6.949480635 | 3.31E-19 |
| hsa-miR-4791 | 186.7263031 | 9.764657543 | 1.81E-13 |
| hsa-miR-143-3p | 3014.137094 | 4.242367581 | 1.25E-12 |
| hsa-miR-3690 | 70.86488948 | 9.209904393 | 3.00E-12 |
| hsa-miR-145-5p | 72.96215294 | 8.781293485 | 4.09E-12 |
| hsa-miR-146b-5p | 572.9246948 | 3.850563079 | 7.29E-12 |
| hsa-miR-150-3p | 60.38153154 | 7.465472022 | 4.02E-11 |
| hsa-miR-223-3p | 3583.963415 | 10.60183039 | 6.42E-11 |
| hsa-miR-197-3p | 1848.704656 | 3.167278515 | 3.68E-10 |
| hsa-miR-6842-3p | 121.4605639 | 5.034134649 | 3.78E-10 |
| hsa-miR-27a-5p | 159.1304428 | 4.762393491 | 2.69E-09 |
| hsa-miR-4286 | 28.41313356 | 7.592582565 | 5.34E-09 |
| hsa-miR-4732-3p | 39.85412873 | -4.344998011 | 9.19E-09 |
| hsa-miR-29a-3p | 264.2422459 | 3.036225197 | 3.23E-08 |
| hsa-miR-23a-3p | 1648.646951 | 2.426234941 | 5.38E-08 |
| hsa-miR-1291 | 24.09578022 | 7.678294911 | 6.73E-08 |
| hsa-miR-140-3p | 6094.803676 | 2.906210556 | 8.46E-08 |
| hsa-miR-361-3p | 518.887784 | 2.698437793 | 9.62E-08 |
| hsa-miR-582-3p | 45.25401955 | 5.187956688 | 1.71E-07 |
| hsa-miR-363-3p | 412.4688189 | -2.480558611 | 2.01E-07 |
| hsa-miR-1299 | 102.3727512 | 4.139411714 | 2.36E-07 |
| hsa-miR-28-3p | 1018.820725 | 2.668213456 | 5.27E-07 |
| hsa-miR-766-3p | 29.59956282 | 5.9824388 | 5.65E-07 |
| hsa-miR-146b-3p | 27.95214056 | 5.751583995 | 6.65E-07 |

19th Dec

Gupta et al

| | | | |
|------------------|-------------|--------------|-------------|
| hsa-miR-146a-5p | 395.7308176 | 2.295825898 | 1.07E-06 |
| hsa-miR-486-3p | 442.3385331 | -2.280314186 | 1.42E-06 |
| hsa-miR-199b-5p | 17.69789788 | 6.652284259 | 1.65E-06 |
| hsa-miR-148a-3p | 21311.06097 | 2.967223068 | 2.14E-06 |
| hsa-miR-769-5p | 78.16221633 | 3.454304058 | 2.22E-06 |
| hsa-miR-132-3p | 13.41828033 | 6.795969882 | 2.82E-06 |
| hsa-miR-504-5p | 16.20689324 | 6.842868855 | 3.34E-06 |
| hsa-miR-92a-3p | 65823.55513 | -2.10142854 | 4.67E-06 |
| hsa-miR-330-3p | 53.90163431 | 3.129351136 | 4.88E-06 |
| hsa-miR-200c-3p | 15.27230031 | 6.716323846 | 5.34E-06 |
| hsa-miR-486-5p | 186570.8541 | -2.309900141 | 5.98E-06 |
| hsa-miR-338-5p | 16.14897785 | 6.511596255 | 7.43E-06 |
| hsa-miR-183-5p | 757.7566497 | -2.260214693 | 7.87E-06 |
| hsa-miR-1273h-5p | 11.10031853 | 6.530890359 | 1.55E-05 |
| hsa-miR-342-5p | 93.52411001 | 3.308610483 | 4.55E-05 |
| hsa-miR-326 | 16.42493563 | 5.988631002 | 4.61E-05 |
| hsa-miR-618 | 15.6716072 | 6.016209684 | 4.61E-05 |
| hsa-miR-191-5p | 2983.128623 | 1.523838499 | 7.79E-05 |
| hsa-miR-27a-3p | 285.7014296 | 1.731405393 | 7.96E-05 |
| hsa-miR-328-3p | 271.7224572 | 2.170776673 | 7.96E-05 |
| hsa-miR-451a | 14357.385 | -1.83622576 | 9.53E-05 |
| hsa-miR-3614-5p | 9.33818402 | 6.123669779 | 0.000106957 |
| hsa-miR-30e-3p | 815.6225605 | 2.360699038 | 0.000125365 |
| hsa-miR-3653-3p | 9.955406247 | 6.067314627 | 0.000138372 |
| hsa-miR-16-2-3p | 99.02227371 | -2.704373872 | 0.000138392 |
| hsa-miR-941 | 1372.569505 | 2.112993367 | 0.000155687 |
| hsa-miR-1273h-3p | 8.79013326 | 5.927996135 | 0.000189765 |
| hsa-miR-584-5p | 74.74437394 | -2.177917358 | 0.000200673 |
| hsa-miR-361-5p | 31.19551383 | 3.652271942 | 0.000286557 |
| hsa-miR-423-5p | 9496.481452 | -1.666500408 | 0.000301254 |
| hsa-miR-425-3p | 23.4899942 | 3.50770916 | 0.000497233 |
| hsa-miR-1908-5p | 5.40110314 | -6.802848578 | 0.000500329 |
| hsa-miR-144-5p | 73.08790204 | -2.608545423 | 0.000614181 |
| hsa-miR-148a-5p | 7.077958372 | 5.991607608 | 0.000826919 |
| hsa-miR-3960 | 21.82641113 | -3.014306593 | 0.000826919 |
| hsa-miR-92b-3p | 284.8388438 | -1.662148164 | 0.001252142 |

19th Dec

Gupta et al

| | | | |
|------------------|-------------|--------------|-------------|
| hsa-miR-625-3p | 147.3917485 | 2.170185206 | 0.001322084 |
| hsa-miR-320a | 3462.527306 | -1.402939938 | 0.00139293 |
| hsa-miR-345-5p | 22.71828536 | 3.943197206 | 0.00139293 |
| hsa-miR-1260a | 50.29735001 | 2.615764632 | 0.001605391 |
| hsa-let-7i-5p | 12361.71358 | -1.302787012 | 0.001797592 |
| hsa-miR-619-5p | 22.7811983 | 3.161529188 | 0.001900387 |
| hsa-miR-122-5p | 3385.264898 | -1.584467253 | 0.002340813 |
| hsa-miR-340-5p | 46.36446243 | 2.653771404 | 0.002544196 |
| hsa-miR-144-3p | 48.36612972 | -2.49500384 | 0.002555714 |
| hsa-miR-126-3p | 892.3500608 | -1.625098791 | 0.003126621 |
| hsa-miR-543 | 129.0107724 | -1.784228026 | 0.003228785 |
| hsa-miR-22-3p | 198.2421283 | -1.339256703 | 0.003317174 |
| hsa-miR-125a-3p | 25.61739412 | 2.647707932 | 0.0045958 |
| hsa-miR-26b-3p | 5.972701619 | 5.518835758 | 0.0045958 |
| hsa-miR-365a-3p | 53.55418216 | 2.123552072 | 0.0045958 |
| hsa-miR-365b-3p | 53.55418216 | 2.123552072 | 0.0045958 |
| hsa-let-7b-5p | 11122.0756 | -1.385051301 | 0.004654547 |
| hsa-miR-340-3p | 9.403598252 | 4.19564441 | 0.007285806 |
| hsa-miR-3158-3p | 143.2936325 | -1.487178473 | 0.00782372 |
| hsa-miR-3909 | 4.660678895 | 5.033669701 | 0.008065745 |
| hsa-miR-505-3p | 19.61789922 | 3.184975964 | 0.009512761 |
| hsa-miR-96-5p | 6.228218724 | -4.412956083 | 0.01160297 |
| hsa-miR-92b-5p | 15.60484631 | -2.774216268 | 0.011905118 |
| hsa-miR-5684 | 14.25740308 | -3.392469579 | 0.012209695 |
| hsa-miR-574-3p | 151.5421548 | 1.44861864 | 0.012209695 |
| hsa-miR-589-5p | 112.3400591 | 1.712421621 | 0.012209695 |
| hsa-miR-1260b | 38.28153971 | 1.901084012 | 0.015737938 |
| hsa-miR-17-5p | 56.12478112 | -1.912960954 | 0.017636633 |
| hsa-miR-4488 | 301.3772581 | 1.686545438 | 0.019800269 |
| hsa-miR-3150b-3p | 9.284489454 | 3.713227496 | 0.020280067 |
| hsa-miR-503-5p | 39.07218516 | -1.757011842 | 0.023641179 |
| hsa-miR-24-2-5p | 7.48136792 | 3.967586096 | 0.024393346 |
| hsa-miR-4508 | 74.78488456 | -1.444481229 | 0.024393346 |
| hsa-miR-193a-5p | 184.9649622 | 1.410027061 | 0.025848637 |
| hsa-miR-148b-3p | 604.5039106 | 1.071494091 | 0.025962098 |
| hsa-miR-24-3p | 347.9262528 | 1.011562924 | 0.025962098 |

19th Dec

Gupta et al

| | | | |
|-----------------|-------------|--------------|-------------|
| hsa-miR-26a-5p | 2978.105792 | 1.023914595 | 0.030449772 |
| hsa-let-7a-5p | 14867.14987 | -1.186931323 | 0.032443997 |
| hsa-miR-1180-3p | 56.26387509 | -1.461006415 | 0.032443997 |
| hsa-miR-128-3p | 443.1001246 | 1.234565868 | 0.032663654 |
| hsa-miR-4732-5p | 37.4933489 | -1.669985619 | 0.033292936 |
| hsa-miR-194-5p | 19.87025713 | -2.652995088 | 0.035040129 |
| hsa-let-7e-5p | 315.5665007 | -1.266168593 | 0.036277702 |
| hsa-miR-222-3p | 1950.75622 | -1.054430196 | 0.04170154 |
| hsa-miR-744-5p | 307.4576353 | 1.101237911 | 0.04395607 |
| hsa-miR-93-3p | 19.14613315 | 2.21447109 | 0.04444623 |
| hsa-miR-28-5p | 15.19613321 | 2.619036378 | 0.047605172 |

899

Total number of miRNAs were 363 in RNA sequencing data;
900 *baseMean = Mean normalized expression of the miRNAs in all the samples;*
901 *padj = adjusted for multiple testing by the Benjamini-Hochberg method;*
902 *niE, non-infected erythrocytes; ePCR-iE, adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes*

903

904

905

906

907

908

909

910

911

912

913

914

915 **Table 3:** miRNAs differentially expressed in cell-conditioned media of human brain endothelial
 916 cells when exposed to 3D7-iE and compared with ePCR-iE after one hour incubation. Positive
 917 FoldChange indicates overexpression in 3D7-iE.

| miRNA | baseMean | log2FoldChange | padj |
|-----------------|-------------|----------------|----------|
| hsa-miR-150-5p | 3628.925319 | 6.447621237 | 8.41E-53 |
| hsa-miR-1246 | 8513.8312 | 6.448500505 | 2.44E-29 |
| hsa-miR-342-3p | 663.0033186 | 4.805719054 | 1.87E-21 |
| hsa-miR-1290 | 958.7797602 | 6.047501723 | 3.28E-19 |
| hsa-miR-143-3p | 3014.137094 | 4.973540967 | 3.06E-17 |
| hsa-miR-223-5p | 359.7886812 | 6.431781207 | 1.96E-16 |
| hsa-miR-4791 | 186.7263031 | 10.38932761 | 2.56E-15 |
| hsa-miR-145-5p | 72.96215294 | 8.773111499 | 5.33E-12 |
| hsa-miR-23a-3p | 1648.646951 | 2.919080408 | 3.83E-11 |
| hsa-miR-146b-5p | 572.9246948 | 3.720217317 | 5.04E-11 |
| hsa-miR-423-5p | 9496.481452 | -2.845800299 | 1.45E-10 |
| hsa-miR-223-3p | 3583.963415 | 10.40824443 | 1.77E-10 |
| hsa-miR-28-3p | 1018.820725 | 3.236927509 | 7.54E-10 |
| hsa-miR-197-3p | 1848.704656 | 3.045327492 | 2.21E-09 |
| hsa-miR-3690 | 70.86488948 | 7.939040485 | 3.04E-09 |
| hsa-miR-363-3p | 412.4688189 | -2.752949366 | 7.66E-09 |
| hsa-miR-451a | 14357.385 | -2.623190083 | 1.10E-08 |
| hsa-miR-4732-3p | 39.85412873 | -4.446862598 | 1.22E-08 |
| hsa-miR-4286 | 28.41313356 | 7.221117949 | 3.72E-08 |
| hsa-miR-1299 | 102.3727512 | 4.296659106 | 8.94E-08 |
| hsa-miR-146a-5p | 395.7308176 | 2.416585365 | 3.27E-07 |
| hsa-miR-320a | 3462.527306 | -2.147110555 | 4.06E-07 |
| hsa-miR-150-3p | 60.38153154 | 5.841471731 | 5.53E-07 |
| hsa-miR-3158-3p | 143.2936325 | -2.671376413 | 6.03E-07 |
| hsa-miR-199b-5p | 17.69789788 | 6.756414418 | 1.41E-06 |
| hsa-miR-326 | 16.42493563 | 7.000378659 | 1.46E-06 |
| hsa-miR-92a-3p | 65823.55513 | -2.206241834 | 1.80E-06 |
| hsa-miR-618 | 15.6716072 | 6.882512894 | 2.54E-06 |
| hsa-miR-27a-5p | 159.1304428 | 3.853017578 | 2.61E-06 |
| hsa-miR-361-5p | 31.19551383 | 4.557109213 | 3.99E-06 |

19th Dec

Gupta et al

| | | | |
|------------------|-------------|--------------|-------------|
| hsa-miR-766-3p | 29.59956282 | 5.475435141 | 7.17E-06 |
| hsa-miR-338-5p | 16.14897785 | 6.585842515 | 7.56E-06 |
| hsa-miR-1180-3p | 56.26387509 | -2.865258808 | 1.15E-05 |
| hsa-miR-486-5p | 186570.8541 | -2.257048303 | 1.36E-05 |
| hsa-miR-486-3p | 442.3385331 | -2.077360932 | 1.53E-05 |
| hsa-miR-140-3p | 6094.803676 | 2.378049094 | 1.89E-05 |
| hsa-miR-1291 | 24.09578022 | 6.218174392 | 2.27E-05 |
| hsa-miR-29a-3p | 264.2422459 | 2.377846317 | 2.52E-05 |
| hsa-miR-4508 | 74.78488456 | -2.537316275 | 3.24E-05 |
| hsa-miR-6842-3p | 121.4605639 | 3.458457239 | 3.89E-05 |
| hsa-miR-200c-3p | 15.27230031 | 6.110652566 | 5.42E-05 |
| hsa-miR-504-5p | 16.20689324 | 6.10449083 | 5.42E-05 |
| hsa-miR-582-3p | 45.25401955 | 4.02067135 | 9.79E-05 |
| hsa-miR-769-5p | 78.16221633 | 2.900427661 | 0.000122239 |
| hsa-miR-27a-3p | 285.7014296 | 1.699710038 | 0.000132728 |
| hsa-miR-625-3p | 147.3917485 | 2.549490741 | 0.000132728 |
| hsa-miR-340-5p | 46.36446243 | 3.201883577 | 0.000214609 |
| hsa-miR-144-3p | 48.36612972 | -3.0660485 | 0.000220627 |
| hsa-miR-425-3p | 23.4899942 | 3.724522238 | 0.000223367 |
| hsa-miR-320b | 420.1406035 | -1.862313231 | 0.000276457 |
| hsa-miR-365a-3p | 53.55418216 | 2.655154806 | 0.000276457 |
| hsa-miR-365b-3p | 53.55418216 | 2.655154806 | 0.000276457 |
| hsa-miR-132-3p | 13.41828033 | 5.410556286 | 0.000380553 |
| hsa-let-7i-5p | 12361.71358 | -1.47141141 | 0.000382512 |
| hsa-miR-30e-3p | 815.6225605 | 2.226049992 | 0.000382512 |
| hsa-miR-92b-5p | 15.60484631 | -4.163857943 | 0.0003924 |
| hsa-miR-146b-3p | 27.95214056 | 4.242630881 | 0.000482005 |
| hsa-miR-92b-3p | 284.8388438 | -1.785328471 | 0.000505668 |
| hsa-miR-4732-5p | 37.4933489 | -2.594968757 | 0.000643162 |
| hsa-miR-122-5p | 3385.264898 | -1.753744088 | 0.000704175 |
| hsa-miR-144-5p | 73.08790204 | -2.558810315 | 0.00089817 |
| hsa-miR-3653-3p | 9.955406247 | 5.420823215 | 0.000963768 |
| hsa-miR-330-3p | 53.90163431 | 2.33736255 | 0.001216256 |
| hsa-miR-2115-3p | 6.041154984 | 5.834660721 | 0.001395787 |
| hsa-miR-183-5p | 757.7566497 | -1.689145385 | 0.001439809 |
| hsa-miR-1273h-3p | 8.79013326 | 5.232979185 | 0.001476418 |

19th Dec

Gupta et al

| | | | |
|------------------|-------------|--------------|-------------|
| hsa-miR-1273h-5p | 11.10031853 | 5.004655278 | 0.001837808 |
| hsa-miR-345-5p | 22.71828536 | 3.888926893 | 0.001844401 |
| hsa-miR-361-3p | 518.887784 | 1.669833063 | 0.001878529 |
| hsa-miR-328-3p | 271.7224572 | 1.756856697 | 0.002066471 |
| hsa-miR-3614-5p | 9.33818402 | 5.084630328 | 0.002066471 |
| hsa-miR-1260a | 50.29735001 | 2.56883531 | 0.002146885 |
| hsa-miR-191-5p | 2983.128623 | 1.22004135 | 0.002216696 |
| hsa-miR-505-3p | 19.61789922 | 3.426913927 | 0.00528521 |
| hsa-miR-4685-3p | 26.37952361 | -2.212963535 | 0.006078573 |
| hsa-miR-148a-3p | 21311.06097 | 1.831991607 | 0.006860876 |
| hsa-miR-126-3p | 892.3500608 | -1.523444179 | 0.007103832 |
| hsa-let-7b-5p | 11122.0756 | -1.342668008 | 0.007601427 |
| hsa-miR-5189-5p | 4.690302347 | -6.195706422 | 0.008125759 |
| hsa-miR-4448 | 19.99074734 | 2.751420355 | 0.008596921 |
| hsa-miR-28-5p | 15.19613321 | 3.329553964 | 0.008697526 |
| hsa-miR-619-5p | 22.7811983 | 2.721712643 | 0.011008689 |
| hsa-miR-5684 | 14.25740308 | -3.504790338 | 0.011818106 |
| hsa-miR-221-5p | 30.33237403 | 2.235527273 | 0.014993794 |
| hsa-miR-24-3p | 347.9262528 | 1.101827408 | 0.015833224 |
| hsa-miR-193a-5p | 184.9649622 | 1.491052572 | 0.020130112 |
| hsa-miR-22-3p | 198.2421283 | -1.113442482 | 0.021327869 |
| hsa-miR-93-3p | 19.14613315 | 2.52716344 | 0.021327869 |
| hsa-miR-2110 | 117.7715931 | -1.410612056 | 0.02301949 |
| hsa-miR-342-5p | 93.52411001 | 2.045398548 | 0.02301949 |
| hsa-miR-543 | 129.0107724 | -1.437070341 | 0.02604373 |
| hsa-miR-155-5p | 135.1369051 | 1.308204109 | 0.02781228 |
| hsa-miR-152-3p | 52.85362465 | 1.703147513 | 0.027818637 |
| hsa-miR-584-5p | 74.74437394 | -1.39071939 | 0.029085671 |
| hsa-let-7e-5p | 315.5665007 | -1.333615616 | 0.030343738 |
| hsa-miR-1908-5p | 5.40110314 | -4.518938959 | 0.033717462 |
| hsa-miR-16-2-3p | 99.02227371 | -1.642902948 | 0.035497673 |
| hsa-miR-3150b-3p | 9.284489454 | 3.477104992 | 0.037288673 |
| hsa-miR-106a-5p | 5.273323169 | -4.723234986 | 0.046728731 |
| hsa-miR-15b-5p | 59.88239009 | 1.339085366 | 0.048947187 |

918
919
920
921

Total number of miRNAs were 363 in RNA sequencing data;

baseMean = Mean normalized expression of the miRNAs in all the samples;

padj = adjusted for multiple testing by the Benjamini-Hochberg method;

3D7-iE, non-adherent 3D7-infected erythrocytes; ePCR-iE, adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes

922 **Table 4:** Number of reads, quality control and number of different miRNAs detected in plasma
923 from Mozambican children recruited in 2006.

| Sample | Total reads | Quality filtered | Complexity filtered | Length filtered | Good quality reads | rRNA | tRNA | miRNA | Unknown | Different miRNAs |
|----------|-------------|---------------------|------------------------|--------------------|-----------------------|---------|---------|---------|----------|---------------------|
| 525881.3 | 10711219 | 1019 | 496 | 3093606 | 7617613 | 1831500 | 651064 | 807691 | 4327358 | 395 |
| 525884.4 | 13220660 | 803 | 702 | 3888349 | 9332311 | 966969 | 596303 | 1966978 | 5802061 | 574 |
| 525885.1 | 10702582 | 333 | 566 | 2319260 | 8383322 | 1232736 | 1136730 | 1751858 | 4261998 | 548 |
| 525887.5 | 13661026 | 1124 | 53 | 2762425 | 10898601 | 594196 | 670121 | 2832128 | 6802156 | 539 |
| 525889.9 | 26426632 | 1073 | 384 | 2617714 | 23808918 | 2136483 | 2578042 | 5776301 | 13318092 | 642 |
| 525891.2 | 9524995 | 439 | 270 | 1873951 | 7651044 | 699777 | 854636 | 1589401 | 4507230 | 593 |
| 525893.6 | 2162887 | 79 | 49 | 120186 | 2042701 | 127077 | 390794 | 440733 | 1084097 | 331 |
| 525896.7 | 17421782 | 1908 | 548 | 5626333 | 11795449 | 1265772 | 839750 | 1030609 | 8659318 | 341 |
| 525898.1 | 3320188 | 126 | 118 | 832015 | 2488173 | 142443 | 215289 | 1663216 | 467225 | 425 |
| 525899.8 | 5937637 | 296 | 454 | 1500015 | 4437622 | 572501 | 700764 | 517740 | 2646617 | 355 |
| 525903.0 | 14957552 | 2 | 276 | 2265449 | 12692103 | 1692270 | 3040674 | 1194073 | 6765086 | 292 |
| 525909.2 | 10293853 | 2128 | 224 | 3483287 | 6810566 | 768196 | 599146 | 1269410 | 4173814 | 412 |
| 544393.2 | 9208074 | 489 | 675 | 2151722 | 7056352 | 1496125 | 1507206 | 883567 | 3169454 | 501 |
| 544394.9 | 13598660 | 996 | 1250 | 6286338 | 7312322 | 1247933 | 758898 | 1477246 | 3828245 | 580 |
| 544395.6 | 16309029 | 973 | 1449 | 3847507 | 12461522 | 3653367 | 2378483 | 1189219 | 5240453 | 554 |
| 544396.3 | 7566573 | 276 | 197 | 1246660 | 6319913 | 627080 | 1632315 | 1027308 | 3033210 | 531 |
| 544397.0 | 6772398 | 266 | 222 | 1805393 | 4967005 | 1187429 | 550612 | 675373 | 2553591 | 498 |
| 544404.3 | 7386300 | 287 | 354 | 1583391 | 5802909 | 433117 | 555473 | 996837 | 3817482 | 581 |
| 544406.7 | 575642 | 0 | 1 | 94684 | 480958 | 34498 | 156803 | 223001 | 66656 | 337 |
| 544407.4 | 322699 | 7 | 47 | 33711 | 288988 | 26869 | 86815 | 40357 | 134947 | 199 |
| 544408.1 | 10702037 | 390 | 839 | 2161657 | 8540380 | 710955 | 2179306 | 1632353 | 4017766 | 663 |
| 544413.5 | 15424105 | 20 | 208 | 3016358 | 12407747 | 2130079 | 1918422 | 2473544 | 5885702 | 276 |
| 544415.9 | 15845270 | 581 | 585 | 4355557 | 11489713 | 1693453 | 1942665 | 3572255 | 4281340 | 757 |
| 544417.3 | 320995 | 6 | 47 | 49727 | 271268 | 79124 | 58275 | 53365 | 80504 | 229 |
| 544423.4 | 12314227 | 511 | 879 | 2620234 | 9693993 | 1146777 | 1257197 | 2022726 | 5267293 | 620 |
| 544425.8 | 6960365 | 244 | 319 | 1393757 | 5566608 | 452538 | 1278619 | 967048 | 2868403 | 473 |
| 544430.2 | 29411214 | 2681 | 2251 | 7142325 | 22268889 | 2330062 | 2430827 | 2447114 | 15060886 | 472 |
| 544431.9 | 12913067 | 374 | 771 | 2019212 | 10893855 | 1553982 | 2423487 | 2087189 | 4829197 | 298 |
| 544434.0 | 9194679 | 428 | 55 | 1158428 | 8036251 | 1187467 | 1514795 | 1642793 | 3691196 | 433 |
| 544436.4 | 10628594 | 352 | 242 | 1424162 | 9204432 | 1030961 | 2030035 | 2940439 | 3202997 | 465 |
| 544439.5 | 18820329 | 990 | 1239 | 3728346 | 15091983 | 1867354 | 2041446 | 1558034 | 9625149 | 659 |

| | | | | | | | | | | |
|----------|----------|------|------|---------|----------|---------|---------|---------|----------|-----|
| 566322.2 | 9096499 | 219 | 526 | 970253 | 8126246 | 222824 | 1176992 | 1440172 | 5286258 | 463 |
| 566323.9 | 12512273 | 307 | 147 | 681565 | 11830708 | 373103 | 468855 | 8338268 | 2650482 | 770 |
| 566324.6 | 7407842 | 271 | 230 | 799057 | 6608785 | 473056 | 1541802 | 2306487 | 2287440 | 644 |
| 566327.7 | 265530 | 5 | 26 | 39505 | 226025 | 23941 | 18230 | 86877 | 96977 | 274 |
| 566329.1 | 575470 | 7 | 48 | 23763 | 551707 | 59080 | 163228 | 133556 | 195843 | 311 |
| 566332.1 | 9282984 | 18 | 577 | 2188722 | 7094262 | 936251 | 1105618 | 2509571 | 2542822 | 310 |
| 566333.8 | 12485750 | 1976 | 85 | 3068214 | 9417536 | 1147898 | 945883 | 1973103 | 5350652 | 669 |
| 566335.2 | 16300010 | 1628 | 450 | 3430462 | 12869548 | 1439268 | 1267034 | 2367655 | 7795591 | 395 |
| 566353.6 | 12299560 | 520 | 92 | 4379950 | 7919610 | 1052903 | 619183 | 2088724 | 4158800 | 612 |
| 566355.0 | 2968770 | 0 | 79 | 1009357 | 1959413 | 328104 | 255943 | 440443 | 934923 | 160 |
| 566356.7 | 15403237 | 1053 | 1726 | 3642172 | 11761065 | 2419028 | 1509598 | 1633826 | 6198613 | 628 |
| 566358.1 | 8943757 | 529 | 1773 | 3677028 | 5266729 | 1105767 | 487154 | 1637474 | 2036334 | 454 |
| 566359.8 | 744578 | 20 | 72 | 58563 | 686015 | 35746 | 148801 | 79994 | 421474 | 288 |
| 566361.1 | 25792113 | 905 | 1378 | 7723560 | 18068553 | 1793988 | 2690970 | 6727806 | 6855789 | 580 |
| 566362.8 | 12021808 | 747 | 24 | 3274341 | 8747467 | 1603501 | 18940 | 10773 | 7114253 | 151 |
| 566364.2 | 1631464 | 99 | 104 | 556133 | 1075331 | 112855 | 251575 | 48887 | 662014 | 274 |
| 566365.9 | 19129131 | 2 | 966 | 1691465 | 17437666 | 2087295 | 2389159 | 7624018 | 5337194 | 399 |
| 566366.6 | 19623668 | 7037 | 92 | 5322923 | 14300745 | 1231391 | 1029852 | 1170845 | 10868657 | 467 |
| 566367.3 | 384010 | 3 | 32 | 97518 | 286492 | 22854 | 26912 | 122521 | 114205 | 150 |
| 579033.4 | 12761288 | 299 | 223 | 2438291 | 10322997 | 4471210 | 1076958 | 2371736 | 2403093 | 570 |
| 579034.1 | 7225891 | 25 | 2766 | 472409 | 6753482 | 472354 | 2250034 | 994990 | 3036104 | 465 |
| 579035.8 | 9863866 | 517 | 265 | 2370430 | 7493436 | 441043 | 567999 | 1734312 | 4750082 | 481 |
| 579036.5 | 145356 | 0 | 13 | 17436 | 127920 | 4210 | 11235 | 65688 | 46787 | 196 |
| 579037.2 | 1493408 | 4 | 82 | 338939 | 1154469 | 47182 | 229698 | 521844 | 355745 | 394 |
| 579038.9 | 10367363 | 371 | 1380 | 3078000 | 7289363 | 639425 | 1550985 | 991123 | 4107830 | 388 |
| 579040.2 | 9253151 | 13 | 408 | 2472738 | 6780413 | 384449 | 1761922 | 500022 | 4134020 | 373 |
| 579042.6 | 15960129 | 470 | 202 | 2728371 | 13231758 | 638919 | 3805700 | 1934893 | 6852246 | 380 |
| 579043.3 | 7089342 | 206 | 697 | 1602007 | 5487335 | 964876 | 1536510 | 687802 | 2298147 | 260 |
| 579045.7 | 1982823 | 2 | 433 | 143776 | 1839047 | 233623 | 490286 | 324346 | 790792 | 305 |
| 579046.4 | 1873456 | 486 | 38 | 806002 | 1067454 | 75715 | 60748 | 43809 | 887182 | 185 |
| 579048.8 | 1082686 | 1 | 50 | 185056 | 897630 | 54474 | 153016 | 135343 | 554797 | 200 |
| 579050.1 | 170063 | 2 | 27 | 17739 | 152324 | 17255 | 29933 | 23521 | 81615 | 160 |
| 579051.8 | 10722970 | 448 | 158 | 1708024 | 9014946 | 642574 | 2552986 | 1186376 | 4633010 | 313 |
| 579052.5 | 4228866 | 219 | 748 | 2256487 | 1972379 | 246201 | 433194 | 222570 | 1070414 | 146 |
| 579053.2 | 8618384 | 462 | 1092 | 1949499 | 6668885 | 354969 | 1025766 | 994142 | 4294008 | 319 |
| 579054.9 | 9386303 | 689 | 143 | 4284092 | 5102211 | 340702 | 1452895 | 638954 | 2669660 | 242 |

19th Dec

Gupta et al

| | | | | | | | | | | |
|----------|----------|------|------|---------|----------|---------|---------|---------|----------|-----|
| 579055.6 | 3526717 | 94 | 80 | 1769909 | 1756808 | 199283 | 294707 | 223967 | 1038851 | 123 |
| 579058.7 | 1792508 | 133 | 10 | 997704 | 794804 | 53040 | 154970 | 126036 | 460758 | 242 |
| 579059.4 | 17665599 | 8 | 910 | 1746197 | 15919402 | 1020271 | 3146816 | 6390514 | 5361801 | 365 |
| 579060.0 | 11438101 | 537 | 771 | 3749312 | 7688789 | 618651 | 1015852 | 548212 | 5506074 | 300 |
| | | | | | | | | 1109671 | | |
| 579061.7 | 33311564 | 3 | 1496 | 2576915 | 30734649 | 2601559 | 5795176 | 6 | 11241198 | 442 |
| 579062.4 | 3451830 | 156 | 2 | 1762819 | 1689011 | 202947 | 239684 | 218299 | 1028081 | 116 |
| 579064.8 | 8994815 | 278 | 178 | 2721236 | 6273579 | 840779 | 987181 | 593171 | 3852448 | 161 |
| 579065.5 | 18176617 | 7425 | 386 | 6172449 | 12004168 | 781469 | 399288 | 948897 | 9874514 | 334 |
| 579068.6 | 5128830 | 305 | 256 | 1520699 | 3608131 | 300353 | 890927 | 810364 | 1606487 | 396 |
| 579069.3 | 45577321 | 37 | 4302 | 2027990 | 43549331 | 926339 | 3622063 | 5903995 | 33096934 | 786 |
| 579075.4 | 9827499 | 20 | 816 | 1032689 | 8794810 | 363164 | 665426 | 1692835 | 6073385 | 515 |
| 579077.8 | 10214090 | 344 | 167 | 1093407 | 9120683 | 1504424 | 989870 | 3501517 | 3124872 | 595 |
| 579078.5 | 4481826 | 234 | 167 | 2157860 | 2323966 | 119110 | 242195 | 281184 | 1681477 | 175 |
| 579079.2 | 1225321 | 30 | 72 | 869796 | 355525 | 78232 | 60481 | 95781 | 121031 | 204 |
| 598991.0 | 8703408 | 2 | 406 | 1378261 | 7325147 | 439304 | 989308 | 2636136 | 3260399 | 546 |
| 598993.4 | 7424401 | 473 | 236 | 3018779 | 4405622 | 292897 | 603224 | 430567 | 3078934 | 181 |

924

925

926

927

928

929 **Table 5:** Spearman correlations between ELISA based HRP2 levels and miRNA relative expression
930 levels (REs) in plasma samples from Mozambican children. HRP2 levels and miRNA REs were
931 log transformed.

932

| miRNA | rho | p value |
|-----------------------------------|--------|---------|
| Children recruited in 2006 | | |
| hsa-miR-10b-5p | 0.415 | 0.020 |
| hsa-miR-378a-3p | 0.422 | 0.020 |
| hsa-miR-4497 | 0.533 | <0.001 |
| Children recruited in 2014 | | |
| hsa-miR-122-5p | -0.016 | 0.892 |
| hsa-miR-320a | 0.121 | 0.320 |
| hsa-miR-1246 | 0.066 | 0.588 |
| hsa-miR-1290 | 0.123 | 0.310 |
| hsa-miR-3158-3p | 0.511 | <0.001 |
| hsa-miR-4497 | 0.401 | <0.001 |

933

934

935

936

937

938

939

940

941

942

943 **Table 6:** PCR efficiencies of each miRNA used for RT-qPCR analysis.

944

| miRNA | PCR efficiencies |
|-----------------|-------------------------|
| hsa-miR-122-5p | 99.6% |
| hsa-miR-320a | 95.3% |
| hsa-miR-1246 | 98.4% |
| hsa-miR-1290 | 103.0% |
| hsa-miR-3158-3p | 91.2% |
| hsa-miR-4497 | 96.9% |
| has-miR-191-5p | 93.1% |
| hsa-miR-30d-5p | 103.8% |
| hsa-miR-148a-3p | 100.1% |
| ath-miR-159a | 103.2% |

945

946

947

948

949

950

951

952

953

954

955

956 **Table 7:** The predicted targets of the two miRNAs (hsa-miR-3158-3p and hsa-miR-4497) validated
957 in children recruited in 2014.

958

| hsa-miR-3158-3p | hsa-miR-4497 |
|-----------------|--------------|
| TXNIP | RUNX1 |
| MAP3K9 | CCNF |
| ZNF704 | CTTN |
| BCL7A | FANCA |
| GATAD2B | NAB2 |
| FBXO46 | NF2 |
| CHST15 | NPY4R |
| FTSJ3 | PRPS1 |
| CTC1 | TPM3 |
| CABP7 | UGT8 |
| C20orf194 | VEGFA |
| IGSF8 | RAB9A |
| KLHL15 | IRX5 |
| NLK | BPNT1 |
| NFASC | APPBP2 |
| LMNB2 | CD226 |
| MRPS18A | ATP1B4 |
| LSM4 | SH2B1 |
| XRCC6 | SDF4 |
| ZBTB39 | MTPAP |
| UBXN2B | TMEM33 |
| RRP7A | DUSP22 |
| ZCCHC14 | RAB22A |
| RANGAP1 | TBC1D24 |

19th Dec

Gupta et al

| | |
|----------|-------------|
| RAB3IP | ZNF490 |
| AMOTL2 | DSN1 |
| ANXA11 | FBXL18 |
| C22orf39 | LRRC27 |
| DDX6 | ATP13A4 |
| CDK2 | HIST1H2AH |
| ENAH | SP140L |
| ENPP5 | CAMK2N2 |
| GDAP1L1 | C10orf71 |
| FOSL1 | FAM83C |
| MMP15 | MIPOL1 |
| PLAG1 | CCNY |
| NANOS1 | PRPS1L1 |
| MRTO4 | CBARP |
| PIGQ | LHFPL3 |
| NLGN1 | C8orf82 |
| RTN2 | PPAN-P2RY11 |
| SAMD4A | CASTOR2 |
| PTPRJ | |
| THSD7A | |
| ZNF281 | |

959

27th June

Gupta et al

960 **Table 8:** Clustering results of DAVID analysis.

961

| Category | Term | Genes | Fold Enrichment | p value | Benjamini p value |
|---------------|---|---|-----------------|---------|-------------------|
| GOTERM_CC_DIR | GO:0030687~preribosome, | PPAN-P2RY11, FTSJ3, | 25.136 | 0.006 | 0.647 |
| ECT | large subunit precursor | MRTO4 | | | |
| GOTERM_BP_DIR | GO:0007399~nervous system | IGSF8, NAB2, VEGFA, | 4.875 | 0.007 | 0.977 |
| ECT | development | NLGN1, BPNT1, PRPS1 | | | |
| GOTERM_CC_DIR | GO:0045335~phagocytic | RAB9A, ANXA11, | 18.691 | 0.011 | 0.605 |
| ECT | vesicle | RAB22A | | | |
| GOTERM_MF_DIR | GO:0000287~magnesium ion | NLK, MTPAP, | 5.237 | 0.015 | 0.902 |
| ECT | binding | PRPS1L1, BPNT1, PRPS1 | | | |
| GOTERM_BP_DIR | GO:0006015~5-phosphoribose | PRPS1L1, PRPS1 | 116.611 | 0.017 | 0.987 |
| ECT | 1-diphosphate biosynthetic process | | | | |
| GOTERM_BP_DIR | GO:0002175~protein | NFASC, UGT8 | 116.611 | 0.017 | 0.987 |
| ECT | localization to paranode region of axon | | | | |
| GOTERM_BP_DIR | GO:0009156~ribonucleoside | PRPS1L1, PRPS1 | 93.288 | 0.021 | 0.974 |
| ECT | monophosphate biosynthetic process | | | | |
| GOTERM_MF_DIR | GO:0004749~ribose phosphate | PRPS1L1, PRPS1 | 85.473 | 0.023 | 0.702 |
| ECT | diphosphokinase activity | | | | |
| GOTERM_CC_DIR | GO:0043231~intracellular | CTTN, MTPAP, | 3.048 | 0.026 | 0.667 |
| ECT | membrane-bounded organelle | RANGAP1, UGT8, RUNX1, ATP13A4, DDX6 | | | |
| GOTERM_MF_DIR | GO:0019003~GDP binding | RAB9A, RAB22A, | 11.871 | 0.026 | 0.641 |
| ECT | | PRPS1 | | | |
| GOTERM_CC_DIR | GO:0005635~nuclear envelope | TMEM33, ANXA11, | 6.112 | 0.027 | 0.602 |
| ECT | | ATP1B4, RANGAP1 | | | |
| GOTERM_CC_DIR | GO:0030027~lamellipodium | ENAH, CTTN, NF2, | 6.074 | 0.027 | 0.542 |
| ECT | | RAB3IP | | | |
| GOTERM_BP_DIR | GO:0030913~paranodal | NFASC, UGT8 | 66.634 | 0.029 | 0.978 |
| ECT | junction assembly | | | | |
| GOTERM_CC_DIR | GO:0000932~cytoplasmic | LSM4, SAMD4A, | 9.345 | 0.04 | 0.627 |

27th June

Gupta et al

| | | | | | |
|---------------|---|--|--------|-------|-------|
| ECT | mRNA processing body | DDX6 | | | |
| GOTERM_MF_DIR | GO:0030371~translation | NANOS1, SAMD4A | 38.851 | 0.049 | 0.798 |
| ECT | repressor activity | | | | |
| GOTERM_CC_DIR | GO:0001726~ruffle | CTTN, NF2, RAB22A | 8.099 | 0.052 | 0.674 |
| ECT | | | | | |
| GOTERM_BP_DIR | GO:0000956~nuclear- | LSM4, MRTO4 | 35.88 | 0.054 | 0.996 |
| ECT | transcribed mRNA catabolic process | | | | |
| GOTERM_BP_DIR | GO:0033962~cytoplasmic | LSM4, DDX6 | 35.88 | 0.054 | 0.996 |
| ECT | mRNA processing body assembly | | | | |
| GOTERM_BP_DIR | GO:0071425~hematopoietic | RUNX1, CTC1 | 33.317 | 0.058 | 0.994 |
| ECT | stem cell proliferation | | | | |
| GOTERM_BP_DIR | GO:0051301~cell division | DSN1, CCNY, CCNF, ANXA11, CDK2 | 3.331 | 0.061 | 0.99 |
| ECT | | | | | |
| GOTERM_BP_DIR | GO:0009165~nucleotide biosynthetic process | PRPS1L1, PRPS1 | 31.096 | 0.062 | 0.983 |
| ECT | | | | | |
| GOTERM_CC_DIR | GO:0042470~melanosome | RAB9A, TMEM33, ANXA11 | 7.217 | 0.063 | 0.708 |
| ECT | | | | | |
| GOTERM_CC_DIR | GO:0005856~cytoskeleton | ENAH, CTTN, NF2, RAB3IP, TPM3 | 3.274 | 0.064 | 0.673 |
| ECT | | | | | |
| GOTERM_MF_DIR | GO:0005161~platelet-derived growth factor receptor binding | PTPRJ, VEGFA | 28.491 | 0.067 | 0.837 |
| ECT | | | | | |
| GOTERM_BP_DIR | GO:0050860~negative regulation of T cell receptor signaling pathway | PTPRJ, DUSP22 | 27.437 | 0.069 | 0.984 |
| ECT | | | | | |
| GOTERM_MF_DIR | GO:0044822~poly(A) RNA binding | PPAN-P2RY11, RRP7A, XRCC6, ANXA11, MTPAP, LSM4, FTSJ3, SAMD4A, MRTO4, DDX6 | 1.892 | 0.075 | 0.828 |
| ECT | | | | | |
| GOTERM_BP_DIR | GO:0009116~nucleoside metabolic process | PRPS1L1, PRPS1 | 24.549 | 0.077 | 0.984 |
| ECT | | | | | |
| GOTERM_BP_DIR | GO:0051894~positive regulation of focal adhesion assembly | PTPRJ, VEGFA | 22.211 | 0.085 | 0.985 |
| ECT | | | | | |
| GOTERM_BP_DIR | GO:0000027~ribosomal large subunit assembly | PPAN-P2RY11, MRTO4 | 22.211 | 0.085 | 0.985 |
| ECT | | | | | |

27th June

Gupta et al

| | | | | | |
|---------------|----------------------------|----------------|--------|-------|-------|
| GOTERM_CC_DIR | GO:0005770~late endosome | RAB9A, RAB22A, | 5.975 | 0.087 | 0.757 |
| ECT | | SDF4 | | | |
| GOTERM_MF_DIR | GO:0019901~protein kinase | PTPRJ, FAM83C, | 2.841 | 0.096 | 0.862 |
| ECT | binding | CCNY, CAMK2N2, | | | |
| | | CD226 | | | |
| GOTERM_BP_DIR | GO:0007422~peripheral | NFASC, UGT8 | 19.435 | 0.096 | 0.987 |
| ECT | nervous system development | | | | |

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985 **Appendix References**

- 986 1. WHO. Guidelines for the treatment of malaria. 3rd ed. 2015. [cited 2020 08/06/2020];
987 Available from: <https://www.who.int/malaria/publications/atoz/9789241549127/en/>
- 988 2. Mayor A, Hafiz A, Bassat Q, Rovira-Vallbona E, Sanz S, Machevo S, et al. Association of
989 severe malaria outcomes with platelet-mediated clumping and adhesion to a novel host receptor.
990 PLoS One. 2011 Apr 29;6(4):e19422.
- 991 3. Roberts DJ, Craig AG, Berendt AR, Pinches R, Nash G, Marsh K, et al. Rapid switching to
992 multiple antigenic and adhesive phenotypes in malaria. Nature. 1992 Jun 25;357(6380):689-92.
- 993 4. Magallon-Tejada A, Machevo S, Cistero P, Lavstsen T, Aide P, Rubio M, et al.
994 Cytoadhesion to gC1qR through Plasmodium falciparum Erythrocyte Membrane Protein 1 in
995 Severe Malaria. PLoS pathogens. 2016 Nov;12(11):e1006011.
- 996 5. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G. The Impact of
997 Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in genetics. 2013;4:94.
- 998 6. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzese JL, et al. MicroRNAs in plasma of
999 pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer
1000 prevention research. 2009 Sep;2(9):807-13.
- 1001 7. Rubio M, Bustamante M, Hernandez-Ferrer C, Fernandez-Orth D, Pantano L, Sarria Y, et al.
1002 Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk. PLoS
1003 One. 2018;13(3):e0193527.
- 1004 8. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase:
1005 microRNA sequences, targets and gene nomenclature. Nucleic acids research. 2006 Jan
1006 1;34(Database issue):D140-4.
- 1007 9. Pantano L, Estivill X, Marti E. SeqBuster, a bioinformatic tool for the processing and
1008 analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic
1009 cells. Nucleic acids research. 2010 Mar;38(5):e34.
- 1010 10. Pantano L, Estivill X, Marti E. A non-biased framework for the annotation and classification
1011 of the non-miRNA small RNA transcriptome. Bioinformatics. 2011 Nov 15;27(22):3202-3.
- 1012 11. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
1013 RNA-seq data with DESeq2. Genome biology. 2014;15(12):550.
- 1014 12. Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL. Normalization of
1015 circulating microRNA expression data obtained by quantitative real-time RT-PCR. Briefings in
1016 bioinformatics. 2016 Mar;17(2):204-12.
- 1017 13. Yeri A, Courtright A, Reiman R, Carlson E, Beecroft T, Janss A, et al. Total Extracellular
1018 Small RNA Profiles from Plasma, Saliva, and Urine of Healthy Subjects. Scientific reports. 2017
1019 Mar 17;7:44061.
- 1020 14. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse
1021 transcription-PCR data: a model-based variance estimation approach to identify genes suited for
1022 normalization, applied to bladder and colon cancer data sets. Cancer research. 2004 Aug
1023 1;64(15):5245-50.
- 1024 15. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et
1025 al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows.
1026 Nucleic acids research. 2013 Jul;41(Web Server issue):W169-73.
- 1027 16. Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild AC, Tsay M, et al. mirDIP 4.1-
1028 integrative database of human microRNA target predictions. Nucleic acids research. 2018 Jan
1029 4;46(D1):D360-D70.
- 1030 17. Andres-Leon E, Gonzalez Pena D, Gomez-Lopez G, Pisano DG. miRGate: a curated
1031 database of human, mouse and rat miRNA-mRNA targets. Database : the journal of biological
1032 databases and curation. 2015;2015:bav035.
- 1033 18. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update
1034 2018: a resource for experimentally validated microRNA-target interactions. Nucleic acids research.
1035 2018 Jan 4;46(D1):D296-D302.

27th June

Gupta et al

- .036 19. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in
.037 behavior genetics research. Behavioural brain research. 2001 Nov 1;125(1-2):279-84.
.038